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The aim of the study was to synthesise new pyranochromene chalcones, flavanones and 
pyrazolines with different substituents, test them for their antimicrobial and antioxidant 
activity and identify the most appropriate substitution pattern for antioxidant and antibacterial 
activity in order to identify lead compounds to develop into antimicrobial and antioxidant 
drugs. 
 
A series of 20 pryanochromene chalcones were synthesized by first adding pyran rings onto 
2,4,6-trihydroxyacetophenone using 2-methyl-3-butenal forming octandrenolone (a 
dichromene acetophenone) with various benzaldehydes as well as pyridine 2-carbaldehyde 
and furan 2-carbaldehyde to form the corresponding chalcones.  A selection of 13 of these 
chalcones was successfully converted to the flavanones using sodium acetate via an 
intramolecular ring closure step.  In addition, 11 of the chalcones were converted to 
pyrazolines using hydrazine (for one set) and phenylhydrazine (for a second set).  An attempt 
to condense octandrenolone with p-nitrobenzaldehyde resulted in the flavone instead of the 
chalcone.  No further reactions were carried out on the flavone.  The chalcone and flavanone 
with the unsubstituted B ring, A-3a and A-4a were known.  In addition, the chalcone with a 
p-methoxy substituent on the B ring was known.  Apart from that, 52 novel molecules 
including 18 chalcones, 12 flavanones, the flavone and 22 pyrazolines were all reported for 
the first time in this work or publications emanating from this work.  The reactions were 
fairly easy to carry out and resulted in good yields of product. 
 
All synthesized compounds were fully characterized using NMR and IR spectroscopy and 
HRMS.  In addition, 9 chalcones, 2 flavanones and octandrenolone was characterized using 
single crystal X-Ray crystallography.  This confirmed that the double bond was in the E-
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conformation in the chalcones and that the configuration at C-2 in the flavanones was S.  The 
X-Ray structures also revealed the planarity of the chromene chalcones.  Comprehensive 
NMR tables assigning each of the 1H and 13C NMR resonances were constructed and will be 
a useful reference to assign the resonances of similar chromene chalcones, flavanones or 
pyrazolines. 
 
The synthesised pyranochromene compounds were screened for their antibacterial, antifungal 
and antioxidant activities.  There was no real trend between any of the substituents on the B 
ring and bioactivity; however certain compounds with particular substitution patterns showed 
much better activity than others.  With regard to antibacterial activity, two Gram positive 
strains, Staphylococcus aureus and Enterococcus faecalis and three Gram negative strains, 
Escherichia coli, Klebsiella pneumonia and Pseudomonas aeruginosa were used in the study.  
The pyrazoline with the meta fluorinated B ring (C-4e) showed the best antibacterial activity 
with IC50 values of between 14.9-29.7 µM.  The ortho trifluoromethyl pyrazoline derivative 
(C-4i) also showed good antibacterial activity, but only against the Gram negative bacteria 
with IC50 values of between 13.3-26.6 µM.  The two most active flavanones had a much 
larger range than the two pyrazolines mentioned above, with A-4a (the unsubstituted 
flavanone) having MICs between 18.7-64.4 µM and the ortho chloroflavanone (A4i) having 
MICs between 29.6-118.2 µM.  Amongst the three sets of compounds, the chalcones showed 
the worst antibacterial activity with the two best compounds, A-3a (unsubstituted B ring) and 
A-3g (4-methoxychalcone) having MICs of between 32.2-128.7 and 119.5-239.0 µM 
respectively.  The activity of the test compounds were compared to that of neomycin, which 




Two other compounds, A-5 (the para nitroflavone) and the 2-trifluoromethyl 
pyranochromene chalcone (B-6) showed very strain specific activity.  A-5 was active against 
S. aureus at a MIC of 2.3 µM and B-6 against all Gram negative strains at MICs between 
13.7-27.5 µM compared to neomycin with a MIC of 16.3 µM. 
  
The synthesized compounds were also tested against four fungal strains (two strains of 
Candida albicans, Candida krusei and Candida parapsilosis).  Several of the chalcones and 
flavanones 3a/4a (unsubstituted B ring), 3d/4d (4-fluorinated B ring), 4f (3-methoxylated B 
ring), 4l (3-nitrated B ring) and 3m (B ring being a naphthalene group) showed good activity 
against all four strains of fungi having MIC values of 28.5-64.4 µM.  The pyrazolines 4c and 
5c (4-brominated B ring), 4f (4-fluorinated B ring), and 4h and 5h (3,4-difluorinated B ring) 
showed good activity (IC50 between 28.5-104.0 µM) against all the fungal species tested 
against, on average approximately 20 times lower in activity than the standard, amphotericin 
B (1.3 µM), with the best activity being shown by 4f (29.7 µM) and 4h (28.5 µM) against C. 
krusei.     
 
The antioxidant properties of the synthesized compounds were also tested using the DPPH 
radical scavenging assay.  Several compounds in all three classes of compounds synthesized 
showed better antioxidant activity than the ascorbic acid standard used, which had an IC50 
value of 220.0 µM.  The chalcones that showed the best antioxidant activity were A-3e (2,4-
difluoro) (IC50 of 230.4 µM), A-3h (2-fluoro-3-methoxy) (IC50 of 233.2 µM), A-3i (2-chloro) 
(IC50 of 228.7 µM) and A-3l (3-nitro) (IC50 of 220.3 µM).  The flavanones A-4i (2-chloro) 
and A-4l (3-nitro) also showed comparable antioxidant activity to the chalcones with IC50 
values of 225.8 and 234.7 µM.  The pyrazolines all showed excellent antioxidant activity 
being up to four times better than ascorbic acid (220.0 µM) in the DPPH assay.  In addition, 
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the H2O2 scavenging assay was carried out on the pyrazolines where again, several of the 
compounds showed 2 fold better activity than ascorbic acid.   
 
In general, several of the compounds synthesised may be good leads for antibacterial, 
antifungal and antioxidant compounds.  The best lead for an antibacterial compound is the 
pyrazoline C-4e (with a meta fluorinated B ring), while several compounds mentioned above 
may be good leads for antifungals and the pyrazolines in general may be good leads for 
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Chapter 1. Introduction 
Chalcones are colored compounds and occur as bright yellow and in some instances red due 
to their highly conjugated nature.  The term chalcone was coined by Kostanecki and Tambor 
in 1899 [1].  They are also known as benzalacetophenones, benzylideneacetophenones, 
phenyl styryl ketones, β-phenyl acrylphenones, γ-oxo-α-γ-diphenyl-α-propylenes and α-
phenyl-β-benzoethylenes.  Their structure is characterized by two aromatic rings joined 
together by an α,β-unsaturated ketone (Figure 1-1).  They are an important class of 
heterocyclic compounds, which are found abundantly in nature, have potential 
pharmacological use and are the precursors to the flavonoids [2-12].  This class of 
compounds have been found to be active in many medicinal bioassays such as anticancer [4, 
7, 9, 13-20], antibacterial [5, 10, 21-26], antifungal [21, 24-26], antioxidant [7, 27, 28], anti-





Figure 1-1  The basic structure of a linear pyranochromene chalcone 
 
Pyrano chalcones and flavonoids arise from cyclisation of a prenyl group onto the aromatic 
ring, resulting in a 2,2-dimethyl-2H-pyrano subunit (Figure 1-1), which has been 
investigated in recent years due to their interesting pharmacological properties.  They have 
shown interesting docking results with antibacterial enzymes [31-33] as well as antibacterial 
[34], antioxidant [35], antileishmanial [36, 37], protein kinase C inhibition [38], anti-
inflammatory [39, 40] and anticancer [19, 20, 41, 42].  Prenyl (2-methyl-2-butenyl) groups 
substituted onto the chalcone core skeleton have been shown to increase the lipophilicity of 
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the molecule [43] which makes it easier for these compounds to enter into cells.  It has also 
been shown that prenylation increases the biological activity of the original flavonoid [37, 44, 
45].  Prenylated flavonoids are found abundantly in nature in the Leguminosae [46-49], 
Moraceae [47, 50-53], Euphorbiaceae [47, 54-57], Rutaceae [58] and Fabaceae [59] families.   
 
Chalcones can easily be converted to heterocyclic compounds by reacting them with different 
chemical reagents (Figure 1-2).  In this work, pyranochromenochalcones were converted to 
the flavanones by an additional step using sodium acetate and ethanol, and pyrazolines by the 
Michael addition using substituted hydrazine hydrates.  Thus, three structural backbones, the 
pyranochromenochalcones, pyranochromenoflavanones and pyranochromenopyrazolines 
were synthesized with the chalcone as an intermediate.  All three scaffolds were tested for 

































Figure 1-2  Various reactions that can be carried out with the chalcone intermediate 
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Synthetic routes to the pyranochalcones and pyranoflavanones 
In order to synthesise pyranochalcones or pyranoflavanones, either the acetophenone or 
benzaldehyde moiety needs to be prenylated first.  Once prenylated, these two substrates can 
then be reacted to produce the chalcone and then the flavanone. 
 
Synthesis of prenylated acetophenone and aldehyde intermediates 
There are a variety of methods available for the synthesis of pyranochalcones [38, 39, 46, 57, 
59, 60, 61], however the most convenient method is the stepwise synthesis of 
pyranochromene acetophenones, which are then condensed with aldehydes in a Claisen-
Schmidt condensation in the presence of alcoholic bases to form the chalcone.  The 
pyranochromene acetophenone intermediate has been synthesized by the condensation of 
hydroxyacetophenones with 3-methylcrotonaldehyde (3-methyl-2-butenal) in either 
anhydrous pyridine [36, 37, 39], Ca(OH)2 [62, 63] or ethylenediamine diacetate [46, 57, 59].  
Other reagents used for pyran ring formation with acetophenones are 3-chloro-3-methylbut-1-
yne in acetone [64].  Prenylation with prenyl bromide followed by cyclisation with 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) also resulted in pyranochromene chalcones 
[65].  These reactions were easy to perform producing good yields.  Beside prenylating the 
acetophenone portion of the molecule, the aldehyde portion was also prenylated using 2-
chloro-2-methyl-but-3-yne and 3,4-dihydroxybenzaldehyde [66], alkylation of 3-
hydroxybenzaldehyde with 2-methyl-3-butyn-2-ol followed by cyclisation in N,N-
dimethylaniline [67].  In this case the prenylated aldehydes were then reacted with 
acetophenones to produce the prenylated chalcones. 
Lee et al. [46, 59] investigated the mechanism of the prenylation reaction of aromatic 
acetophenones with 3-methyl-2-butenal and ethylenediaminediacetate (EDDA).  They 




























Figure 1-3  Mechanism of prenylation 
 
Condensation reactions of acetophenone and benzaldehyde intermediates to chalcones 
The most common method of preparing chalcones is the Claisen-Smith condensation of 
appropriate benzaldehydes and acetophenones, which is followed by dehydration.  In order 
for this reaction to be successful, various bases such as KOH [36-37, 40, 46, 57, 60-62, 65, 
68], NaOH [19, 62], LDA [59] and NaH [36] in polar solvents such as EtOH, CH3OH and 
THF were used.  Mali et al. [68] used cetyltrimethylammonium bromide (CTAB), an amine 
based cationic quaternary surfactant, under basic conditions to form chalcones with 
prenylated pyranoacetophenone and benzaldeydes that was an intermediate for (±) Maxima 
flavanone A.  In addition to the Claisen-Smith condensation, more interesting synthetic 
protocols have been reported such as the Pd-mediated Suzuki coupling between cinnamoyl 
chlorides and phenyl boronic acids [69], and the carbonylative Heck coupling with aryl 
halides and styrene in the presence of carbon monoxide [70].  Chalcones were also rapidly 
synthesized by microwave in good yields using aqueous potassium hydroxide [71].  
 
The mechanism (Figure 1-4) of this reaction involves the abstraction of a proton from the 
methyl group of the acetophenone forming an enolate anion, which then adds to the 
electrophilic carbonyl of benzaldyde forming the alcohol, which is subsequently dehydrated 


























Figure 1-4  Mechanism of chalcone formation 
 
Conversion of chalcones to flavanones  
Sodium acetate [65, 66] in ethanol is most commonly used to cyclise chalcones to flavanones.  
The only drawback of this reaction is long reaction times of 2-4 days.  Mali et al. [68] used 
KF-celite to carry out the cyclisation of chalcones to flavanones in good yields in shorter 
reaction times of 32-48 hours.  
 
The mechanism (Figure 1-5) involves self-condensation of chalcone to produce flavanone.  
This reaction involves the abstraction of a proton from the ortho hydroxy group of the 
chalcone forming an oxyanion.  This then adds to the alkene, which in turn leads to the 





















Pyrazoline (Figure 1-6) is a five-membered heterocyclic ring having two adjacent nitrogen 
atoms within the ring.  It has an endocyclic double bond, is basic in nature and has three 
possible tautomeric structures with the structure shown in (Figure 1-6) being the most stable.  
Pyrazolines can be considered as a cyclic hydrazine moiety.  Amongst the nitrogen 
containing five membered heterocycles, pyrazolines have proved to be amongst the most 
useful frameworks for biological activity [24, 74, 75].  It is widely used as synthons in 
organic synthesis and the chemistry of pyrazolines was reviewed by Wiley et al. [76].  
Pyrazolines possess a wide spectrum of biological activities.  They are reported to have 
antiamoebic [77], antimicrobial [78-84], MAO inhibitor [85-86], antioxidant [7, 84, 87, 88], 
anti-inflammatory [7, 88-91], anti-analgesic [84, 90], and anticancer and antimycobacterial 
activities [7, 92-95]. 
 
 
Figure 1-6  General structure of pyrazoline 
 
Conversion of chalcones to pyrazolines 
Chalcones can be converted to pyrazolines using hydrazine hydrate or phenyl hydrazine 
hydrate in ethanol.  The reaction probably takes places through in situ formation of an 
appropriate β unsaturated hydrazone intermediate which cyclizes to produce pyrazolines.  
 
There are two possible mechanisms for formation of pyrazolines from chalcones and 
hydrazine.  In first mechanism (Figure 1-7, Mechanism A), hydrazine reacts with chalcone to 
form hydrazone which undergoes an intramolecular Michael addition to form pyrazoline. In 
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the second mechanism (Figure 1-7, Mechanism B), the steps are reversed, where a Michael 





































































Figure 1-7  Possible mechanisms for pyrazoline formation 
 
Biological importance of pyranochalcones, pyranoflavanones and pyranopyrazolines 
Chalcones, flavanones and pyrazolines with a pyran group as part of the core structure have 
shown biological activity in a range of bioassays including antibacterial, anticancer, protein 
kinase inhibition, anti-inflammatory, antileishmanial, interleukin-1 inhibition, anti-HIV and 




Pongachalcone I (1) is a natural linear pyranochalcone which also contains a hydroxy and 
methoxy group.  It was isolated from Tephrosia deflexa [96] and has been reported to have 
antibacterial activity against Pseudomonas putida.  This activity was supported by molecular 
docking studies of pongachalcone with TtgR (multi-drug binding protein in Pseudomonas 
putida (PDB Code: 2UXI).  Pongachalcone showed good binding affinity to this protein [31-
33]. 
 
Prenylated dihydroflavonols from Mundulea suberosa also showed antibacterial activity 
against Bacillus subtilis and Pseudomonas aeruginosa [97].  Of these, 5-methyl lupinifolinol 




Dehydrocycloxanthohumol (3) isolated from hops (Humulus lupulus) [42] showed a dose-
dependent (0.1 to 100 mM) decrease in the growth of human breast cancer (MCF-7), colon 
cancer (HT-29) and ovarian cancer (A-2780) cells in vitro, with the best activity being shown 





Rao et al [98] also observed that flavonoids containing prenyl groups showed higher 
inhibitory activity than their non-prenylated analogues against the MCF-7 cell line.  They 





The synthetic benzopyrano xanthone carbonate (5a) and diol (5b) showed significant 




The dihydropyranoflavanols 6a-c isolated from Dunbaria longeracemosa showed weak 
cytotoxicity against five cancer cell lines, KB (human mouth epidermal carcinoma), HepG2 
(human hepatocellular liver carcinoma), HuCCA-1 (human cholangiocarcinoma), A549 
(human lung carcinoma), and S102 (human liver cancer).  They were also found to inhibit 
aromatase with an IC50 value of 0.3, 0.4 and 1.2 µM respectively.  The pyranoflavonol, 
sericetin (6d) also exhibited cytotoxicity against the KB and HepG2 cancer cell lines.  





The pyranochromenoflavanones 7a and 7b isolated from Mundulea chapelieri were found to 





Protein kinase inhibitors 
Protein kinases are enzymes that add a phosphate (PO4) group to a protein or other organic 
molecules.  This phosphorylation is necessary in some cancers and anti-inflammatory 
conditions.  Inhibition of these kinases prevent phosphorylation and hence cancers and anti-
inflammatory responses.  Rottlierin analogues (8a) were shown to selectively inhibit protein 
kinase C delta (PKC-δ) with an IC50 of 3.0-6.0 µM [38].  Other analogues of rottlierin such as 







The dimethoxypyranochalcone 9 showed remarkable in vitro and in vivo anti-inflammatory 
activity comparable to FDA approved indomethacin [39].  The pyrazoline derivative 10 also 





Antileishmanial activity  
Pyranochalcones such as 11b has shown activity against extracellular promastigotes and 
intracellular amastigotes of Leishmania donavani residing within murine macrophages in 
concentrations ranging from 0.25 to 50 µg mL-1 [37].  It was evidently clear from this study 
that pyran ring was a key feature to antileishmanial activity as 11b containing the pyran 
group showed better activity (87 and 49% inhibition at 50 µg mL-1 against promastigotes and 
amastigotes, respectively) than 11a (60 and 15% inhibition at 50 µg mL-1), which did not 
















The synthesized open prenylated chalcone 12a and the pyran chalcone 12b were also 
significantly more active than then standard antileishmanial drugs, Miltefosine and sodium 






Interleukin 1 is a protein responsible for inflammatory responses.  The pyran chalcone, 
pongapinone A 13a and the open prenylated pongapinone B 13b were isolated from the bark 
of Pongamia pinnata.  Pongapinone A 13a exhibited inhibitory activity upon interleukin-1 
prodution with IC50 values of 2.5 µg mL







HIV reverse transcriptase inhibition 
Mckee et al. [102] isolated six isoflavanoids from plants, marine and microbial organisms, 
which were tested for anti-HIV activity in the NCI’s XTT-based primary screen.  Two of the 
six compounds, 5-deoxyglyasperin F 14a and 2′-hydroxyneobavaisoflavanone 14b displayed 
moderate activity with EC50 values of 11.5 and 7.6 µg mL











14a 14b  
 
Inhibition of NADH:ubiquinone oxidoreductase 
In eukaryotes, NADH:ubiquinone oxidoreductase is located in the inner mitochondrial 
membrane and is one of the "entry enzymes" of cellular respiration or oxidative 
phosphorylation in the mitochondria. It catalyzes the transfer 
of electrons from NADH to coenzyme Q10 (CoQ10). 
 
Lonchocarpusone 15a and 4-hydroxy-3-methoxylonchocarpin 15b showed IC50 values of 4.4 







Monoamine oxidase (MAO) A and B inhibitors 
Monoamine oxidase inhibitors (MAO inhibitors), are chemicals which inhibit the activity of 
the monoamine oxidase enzyme and prevent the breakdown of monoamine oxidase 
neurotransmitters.  Inhibition of both Type A and B monoamine oxidase treats depression and 
anxiety. 
N-substituted-3-[(2'-hydroxy-4'-prenyloxy)-phenyl]-5-phenyl-4,5-dihydro-(1H)-pyrazolines 








Hypothesis and aims 
It is hypothesized that synthesizing chalcones, flavanones and pyrazolines with 
pyranochromene moieties would lead to bioactive molecules, since similar molecules have 
shown a vast array of bioactivity.   
 
The aim of the study is to synthesise new pyranochromene chalcones, flavanones and 
pyrazolines and test these compounds for antimicrobial and antioxidant activity.  More 
specifically, a variety of derivatives with different functional groups on the pyranochromene 
chalcone, flavanone or pyrazoline scaffold were targeted for synthesis.  The main aim is to 
find the most appropriate substitution pattern giving the best antioxidant and antibacterial 
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Chapter 2. Synthesis and structure elucidation of a series of 
pyranochromene chalcones and flavanones using 1D and 2D NMR 
spectroscopy and X-Ray crystallography 
 
Abstract 
A series of novel pyranochromene chalcones and corresponding flavanones were synthesized.  
This is the first report on the confirmation of the absolute configuration of chromene-based 
flavanones using X-ray crystallography.  These compounds were characterized by 2D NMR 
spectroscopy and their assignments are reported herein.  The 3D structure of the chalcone 3b 
and flavanone 4g was determined by X-ray crystallography and the structure of the flavanone 
confirmed to be in the S configuration at C-2.  
 
Keywords 





Chalcones and flavanones form a large and important group of naturally occurring secondary 
metabolites [1].  Chalcones are important intermediates for the synthesis of biologically 
active compounds such as flavone, flavonol, flavanone, isoflavone and their derivatives [2].  
Besides having a physiological role in plants, flavonoids have also been reported to have a 
wide variety of biological activities, including anti-inflammatory, antiviral, antiprotozoal, 
antioxidant, cardiovascular and anti-carcinogenic properties [2]. 
 
A five-membered prenyl moiety on a benzene ring cyclized with an oxygen atom on an 
adjacent position leads to a benzopyran or chromene molecule with a second such cyclisation 
leading to a pyranochromene such as the naturally occurring octandrenolone [3,4], O-
methyloctandrenolone [4-5], trans-3''',4'''-dihydro-3''',4'''-dihydroxy-O-methyloctandrenolone 
[4], trans-3'',4''-dihydro-3'',4''-dihydroxy-O-methyloctandrenolone [4], flemiculosin [6], 
laxichalcone [7], 3-deoxy-MS-II [3,8,9] and MS-II [3,8].  The flavanone (4a) 3-deoxy–MS-II 
(Scheme 2-1), which incorporates pyranochromene moieties was isolated from the 
methanolic extracts of the bark and leaf of Mundulea chapelieri and exhibited activity against 
a human ovarian cancer cell line [8].  Shortly afterward its synthesis was reported [3].  The 
synthesis of six chalcones with an octandrenolone moiety was also reported [10].  Several 
other pyranochromene chalcones and flavonoids were isolated from Mundela suberosa and 
Mundela sericea and have exhibited interesting biological activities including antimicrobial 
and ornithine decarboxylase activity [8,11-17].  A pyranochromene chalcone, (-)-rubranine 
with prenyl groups on the pyran rings was also isolated from Aniba rosaedora [18].  Two 
series of prenylated chromenochalcones were also synthesized and tested for their 
antileishmanial and antimalarial activity where several compounds showed good activity [19-
20].   
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In our ongoing study on synthesizing fluorinated pharmaceuticals, we have prepared several 
fluorinated chalcones and flavanones with the pyranochromene moiety. 
 
Herein we report the NMR elucidation of these fluorinated pyranochromene chalcones and 
flavanones, which is slightly more complicated than the oxygenated or chlorinated molecules 
due to the fluorine atom being NMR active and coupling with both hydrogen and carbon.  We 
used X-ray crystallography and NMR studies to provide a full structural elucidation of these 
novel pyranochromene chalcones and flavanones.  
 
Experimental 
Reagents and chemicals used in this study were purchased from Sigma Aldrich via Capital 
Lab, South Africa and were reagent grade.  All organic solvents were redistilled and dried 
according to standard procedures.  Optical rotations were recorded using a PerkinElmerTM, 
Model 341 Polarimeter with a 10 cm flow tube.  Melting points were measured using a Stuart 
Scientific Melting Point Apparatus SMP3.  IR spectra were recorded on a Perkin Elmer 
Spectrum 100 FT-IR spectrometer with universal ATR sampling accessory.  High-resolution 
mass data was obtained using a Bruker microTOF-Q II ESI instrument operating at ambient 
temperatures, with a sample concentration of approximately 1 ppm.  Thin layer 
chromatography (TLC) was performed using Merck Kieselgel 60 F254 plates.  Crude 
compounds were purified with column chromatography using silica gel (60–120 mesh) as the 
stationary phase and varying combinations of solvents depending on the sample to be 
purified.   
 
The 1H and 13C NMR spectra were recorded at 298 K with 5-10 mg samples dissolved in 0.5 
mL of CDCl3 in 5 mm NMR tubes using a Bruker Avance
III 400 MHz NMR spectrometer 
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(9.4 T; Bruker, Germany) (400.22 MHz for 1H, 100.63 MHz for 13C and  376.58 Hz for 19F. 
The digital digitizer resolution was set at 22 for both the 1H and 13C NMR experiments.  
Chemical shifts (δ) are reported in ppm and coupling constants (J) in Hz.  The 1H and 13C 
chemical shifts of the deuterated solvent were 7.24 and 77.0 respectively, referenced to the 
internal standard, TMS.  For the 19F NMR spectra, the chemical shift of trifluorotoluene 
(TFT) (0.05% in CDCl3) was referenced at -62.73.  For the 
1H NMR analyses, 16 transients 
were acquired with a 1s relaxation delay using 32K data points.  The 90° pulse duration was 
10.0 µs, and the spectral width was 8223.68 Hz.  The 13C NMR spectra were obtained with a 
spectral width of 24038.46 Hz using 64K data points.  The 90° pulse duration was of 8.4 µs.  
For the 19F NMR spectra, the spectral width was 89285.71 Hz using 131K data points and the 
90° pulse duration was 12.5 µs.  For the two dimensional experiments including COSY, 
NOESY, HSQC and HMBC, all data were acquired with 4K × 128 data points (t2 × t1).  The 
mixing time for the NOESY experiment was 0.3 s, and the long range coupling time for the 
HMBC experiment was 65 ms.  All data were analysed using Bruker Topspin 2.1 (2008) 
software.   
 
Synthesis 
The prenylated flavanones (4a-h) were prepared in rather moderate overall yields (30-55%) 
in a three step reaction (Scheme 2-1) where 2',4',6'-trihydroxyacetophenone was prenylated at 
the 2' and 4' positions with 3-methyl-2-butenal in basic conditions under reflux resulting in 
the dichromene acetophenone intermediate 2 [21], which then underwent a Claisen-Schmidt 
condensation reaction with various substituted benzaldehydes to produce chalcones 3a-h in 




Scheme 2-1  Synthetic scheme for the synthesis of pyranochromene flavanones 4a-h.  i) 3-
methyl-2-butenal, pyridine, 110°C, reflux; ii) substituted benzaldehydes, KOH, EtOH/H2O, 
rt; iii) NaOAc, EtOH, 80°C, reflux. 
 
For the synthesis of octandrenolone (1-(5-Hydroxy-2,2,8,8-tetramethyl-2H,8H-pyrano[2,3-
f]chromen-6-yl)ethanone) (2), the method in Pawar et al. [21] was followed and the NMR 
data compared with that of an authentic sample prepared earlier [21]. 
 
The pyranochromene chalcones 3a – 3h were synthesized according to the methods reported 
earlier in Pawar et al. [22] and the compounds purified by flash column chromatography to 
produce pure brown solids.  For the 1H and 13C NMR data, see Table 2-1 and Table 2-2. 
 
1-(5-Hydroxy-2,2,8,8-tetramethyl-2H,8H-pyrano[2,3-f]chromen-6-yl)-3-phenylpropenone 




propenone (3b). Yield 64%; mp 110 - 111 oC.  19F NMR (376 MHz, CDCl3) δ -112.95; IR 
(neat) υmax = 2963, 2923, 1627, 1583, 1539, 1339, 1181, 1137, 1109 cm
-1; HRMS m/z 





propenone (3c).  Yield 90%; mp 150 - 151 oC.  19F NMR (376 MHz, CDCl3) δ -112.63; IR 
(neat) υmax = 2971, 2928, 1630, 1584, 1451, 1135, 1112 cm
-1; HRMS m/z 429.1472 [M+Na]+ 
(calcd. for C25H23O4FNa 429.1478). 
 
3-(4-Fluorophenyl)-1-(5-hydroxy-2,2,8,8-tetramethyl-2H,8H-pyrano[2,3-f]chromen-6-yl)-
propenone (3d). Yield 90%; mp 143 - 144 oC.  19F NMR (376 MHz, CDCl3) δ -109.92; IR 
(neat) υmax = 2971, 2928, 1631, 1585, 1468, 1135, 1113 cm
-1; HRMS m/z 429.1477 [M+Na]+ 
(calcd. for C25H23O4FNa 429.1478). 
 
3-(2,4-Difluorophenyl)-1-(5-hydroxy-2,2,8,8-tetramethyl-2H,8H-pyrano[2,3-f] chromen-6-
yl)-propenone (3e). Yield 74%; mp 154 - 155 oC.  19F NMR (376 MHz, CDCl3) δ -106.57, -
108.54; IR (neat) υmax = 2977, 2931, 1630, 1612, 1582, 1136 cm
-1; HRMS m/z 447.1393 
[M+Na]+ (calcd. for C25H22O4F2Na 447.1384). 
 
1-(5-Hydroxy-2,2,8,8-tetramethyl-2H,8H-pyrano[2,3-f]chromen-6-yl)-3-(3-methoxyphenyl)-
propenone (3f). Yield 77%; mp 95 - 96 oC.  IR (neat) υmax = 2975, 2924, 1640, 1625, 1586, 




propenone (3g). Yield 85%; mp 125 - 126 oC.  IR (neat) υmax = 2977, 2968, 1602, 1578, 1532, 





f]chromen-6-yl)-propenone (3h). Yield 65%; mp 122 - 123 oC.  19F NMR (376 MHz, CDCl3) 
δ -136.22; IR (neat) υmax = 2968, 2926, 1632, 1605, 1581, 1276, 1151, 1132, 1113 cm
-1; 
HRMS m/z 459.1579 [M+Na]+ (calcd. for C26H25O5FNa 459.1584). 
 
Table 2-1 1HNMR shifts of the pyranochromene acetophenone intermediate 2 and 
pyranochromene chalcones 3a – 3h  
δ of 1H (J, Hz) 
No. 2* 3a* 3b 3c 3d 3e 3f 3g 3h 
OH 14.00 (s) 14.37 (s) 14.36 (s) 14.24 (s) 14.31 (s) 14.32 (s) 14.34 (s) 14.49 (s) 14.33 (s) 
OCH3 - - - - - - 3.84 (s) 3.85 (s) 3.91 (s) 
CH3 2.65 (s) - - - - - - - - 









3 - 7.40 (s) 7.12 (dd, 
11.0, 
8.8) 




- 6.93 (d, 
8.3) 
- 




- - 6.94 (dd, 
8.08, 
2.08) 
- 6.98 (dt, 
8.0, 1.2) 
































































1'' 6.58 (d, 
10.1) 














2''# 5.45 (d, 
10.1) 














4''/5''† 1.49 (s) 1.55 (s) 1.54 (s) 1.54 (s) 1.54 (s) 1.53 (s) 1.55 (s) 1.55 (s) 1.54 (s) 
1''' 6.65 (d, 
10.1) 














2'''# 5.43 (d, 
10.1) 














4'''/5'''† 1.43 (s) 1.45 (s) 1.45 (s) 1.46 (s) 1.45 (s) 1.45 (s) 1.45 (s) 1.45 (s) 1.45 (s) 
 
* NMR at 600 MHz; # and † indicate resonances that can be interchanged. 
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Table 2-2  13C NMR shifts of pyranochromene chalcones 2 and 3a – 3h 
δ of 13C (J, Hz) 
No. 2* 3a 3b 3c 3d* 3e 3f 3g 3h 








137.2 128.6 124.5 (d, 
9.2) 









113.1 130.1 151.8 (d, 
252.7) 








160.1 114.5 148.5 
(d, 10.6) 









116.8 161.7 114.6 (d, 
2.1) 








130.1 114.5 124.2 (d, 
4.8) 








121.2 130.1 121.0 (d, 
2.1) 
7 - 142.3 135.4 140.5 (d, 
2.5) 
140.9 134.4 142.2 142.4. 135.0 (d, 
2.4) 




128.0 124.9 130.6 (d, 
7.7) 
9 203.5 193.1 193.1 192.7 192.9 192.9 193.0 193.0 193.0 
1' 105.7 106.1 106.1 106.1 106.1 106.1 106.1 106.1 106.1 
2' 160.7 161.6 161.7 161.6 161.6 161.7 161.6 161.5 161.7 
3' 102.5 102.8 102.8 102.8 102.8 102.8 102.8 102.8 102.8 
4' 155.2 155.5 155.6 155.7 155.5 155.7 155.5 155.3 155.6 
5' 102.4 102.7 102.7 102.7 102.7 102.7 102.7 102.7 102.7 
6' 156.9 156.4 156.5 156.4 156.3 156.4 156.4 156.3 156.5 
1'' 116.6 116.8 116.6 116.7 116.8 116.6 116.4 116.8 116.6 
2''# 125.5 125.6 125.2 125.6 125.6 125.6 125.6 125.5 125.5 
3''ǂ 78.4 78.6 78.7 78.6 78.5 78.6 78.5 78.4 78.7 
4''/5''† 28.5 28.6 28.6 28.6 28.6 28.6 28.6 28.6 28.6 
1''' 116.3 116.4 116.4 116.3 116.4 116.4 116.3 116.5 116.4 
2'''# 124.9 124.9 125.5 125.0 124.9 125.1 124.9 125.4 125.1 
3'''ǂ 78.3 78.5 78.6 78.5 78.4 78.5 78.4 78.3 78.5 
4'''/5'''† 28.2 28.3 28.0 28.3 28.3 28.1 28.3 28.3 28.1 
OCH3/CH3 33.4 - - - - - 55.4 55.6 55.6 
 
*  NMR at 600 MHz; #, ǂ and † indicate that assignments may be interchangeable. 
 
General procedure for the synthesis of pyranochromene flavanones 4a – h 
To a solution of sodium acetate (188 mg, 3.0 mmol) in ethanol (10 mL), pyranochromene 
chalcones 3a-h (0.3 mmol) was added at room temperature.  The reaction mixture was 
refluxed for 48 h at 80°C.  The solvent was distilled off under reduced pressure and the 
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residue was dissolved in water (20 mL).  After acidifying with 2 M HCl (20 mL), the mixture 
was extracted with ethyl acetate (3 × 30 mL), washed with water and dried over anhydrous 
MgSO4.  Removal of the solvent followed by flash column chromatography on silica gel 
afforded the pure pyranochromene flavanones as yellow solids.  For the 1H and 13C NMR 
data see Table 2-3 and Table 2-4. 
 
6,6,10,10-Tetramethyl-2-phenyl-2,3-dihydro-6H,10H-dipyrano[2,3-f;2',3'-h]chromen-4-one 
(4a).  Yield 55%; mp 144 – 145 oC.  IR (neat) υmax = 2923, 2853, 1729, 1677, 1637, 1571, 
1434, 1363, 1136, 1116 cm-1.   
 
2-(2-Fluorophenyl)-6,6,10,10-tetramethyl-2,3-dihydro-6H,10H-dipyrano[2,3-f;2',3'-
h]chromen-4-one (4b) Yield 38%; mp 148 – 150 oC.  19F NMR (376 MHz, CDCl3) δ -118.38; 
IR (neat) υmax = 2966, 2922, 1677, 1637, 1571, 1433, 1364, 1135, 1117 cm
-1; HRMS m/z 
429.1476 [M+Na]+ (calcd. for C25H23O4FNa 429.1478). 
 
2-(3-Fluorophenyl)-6,6,10,10-tetramethyl-2,3-dihydro-6H,10H-dipyrano[2,3-f;2',3'-
h]chromen-4-one (4c)  Yield 46%; mp 92 – 93 oC.  19F NMR (376 MHz, CDCl3) δ -112.06; 
IR (neat) υmax = 2968, 2923, 1678, 1643, 1571, 1162, 1136, 1118 cm
-1; HRMS m/z 429.1471 
[M+Na]+ (calcd. for C25H23O4FNa 429.1478). 
 
2-(4-Fluorophenyl)-6,6,10,10-tetramethyl-2,3-dihydro-6H,10H-dipyrano[2,3-f;2',3'-
h]chromen-4-one (4d) Yield 36%; mp 112 – 113 oC.  19F NMR (376 MHz, CDCl3) δ -113.29; 
IR (neat) υmax = 2968, 2924, 2854, 1681, 1638, 1572, 1512, 1462, 1436, 1132, 1116 cm
-1; 





h]chromen-4-one (4e). Yield 31%; mp 158 – 159 oC.  19F NMR (376 MHz, CDCl3) δ -
109.62, -114.22; IR (neat) υmax = 2978, 2925, 1679, 1641, 1590, 1570, 1132, 1113 cm
-1; 
HRMS m/z 447.1384 [M+Na]+ (calcd. for C25H22O4F2Na 447.1384). 
 
2-(3-Methoxyphenyl)-6,6,10,10-tetramethyl-2,3-dihydro-6H,10H-dipyrano[2,3-f;2',3'-
h]chromen-4-one (4f) Yield 40%; mp 80 – 81 oC.  IR (neat) υmax = 2969, 2923, 2853, 1678, 




h]chromen-4-one (4g). Yield 46%; mp 141 – 142 o C.  IR (neat) υmax = 2975, 2923, 2853, 
1684, 1634, 1613. 1592, 1571, 1245, 1136, 1115 cm-1; HRMS m/z 441.1674 [M+Na]+ (calcd. 
for C26H26O5Na 441.1678). 
 
2-(2-Fluoro-3-methoxyphenyl)-6,6,10,10-tetramethyl-2,3-dihydro-6H,10H-dipyrano[2,3-
f;2',3'-h]chromen-4-one (4h). Yield 54%; mp 100 – 101o C.  19F NMR (376 MHz, CDCl3) δ -
140.91; IR (neat) υmax = 2969, 2926, 1681, 1634, 1590, 1572, 1135, 1115, 1088 cm
-1; HRMS 
m/z 459.1576 [M+Na]+ (calcd. for C26H25O5FNa 459.1584).  
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Table 2-3  1H NMR shifts of pyranochromene flavanones 4a – h  
δ of 1H (J, Hz) 
No. 4a 4b 4c 4d 4e 4f* 4g 4h 
















































2' 7.42 - 7.36 
(m) 




- 7.01 (s) 7.37 (d, 
8.6) 
- 
3' 7.42 - 7.36 
(m) 
7.11 – 7.06 
(m) 




- 6.93 (d, 
8.7) 
- 
4' 7.42 - 7.36 
(m) 
7.37 – 7.31 
(m) 
7.07 - 7.02 
(m) 
- - 6.90 – 6.89 
(m) 
- 7.15 - 7.11 
(m) 














6.99 - 6.95 
(m) 















7.15 - 7.11 
(m) 
































4''† 1.53 (s) 1.52 (s) 1.52 (s) 1.51 (s) 1.52 (s) 1.52 (s) 1.52 (s) 1.51 (s) 
5''† 1.49 (s) 1.49 (s) 1.48 (s) 1.48 (s) 1.49 (s) 1.49 (s) 1.49 (s) 1.49 (s) 
































4'''† 1.46 (s) 1.46 (s) 1.46 (s) 1.45 (s) 1.46 (s) 1.46 (s) 1.45 (s) 1.45 (s) 
5'''† 1.44 (s) 1.44 (s) 1.44 (s) 1.43 (s) 
 
1.44 (s) 1.44 (s) 1.43 (s) 1.43 (s) 
OCH3 - - - - - 3.83 (s) 3.82 (s) 3.90 (s) 
 





Table 2-4  13C NMR shifts of pyranochromene flavanones 4a- h 
δ of 1H (J, Hz)  
No. 4a 4b 4c 4d 4e 4f* 4g 4h 




78.5 73.1 (d, 
2.6) 
79.0 78.9 73.4 (d, 
4.28) 
3 46.1 45.0 46.0 46.0 44.9 46.2 45.9 44.9 
4 188.9 188.5 188.3 188.6 188.3 188.9 189.1 188.6 
5 154.5 154.5 154.5 154.4 155.4 154.5 154.4 154.5 
6 102.5 102.6 102.5 102.5 102.5 102.6 102.5 102.6 
7 156.1 156.2 156.1 156.1 156.2 156.1 156.1 156.2 
8 104.8 104.9 104.9 104.8 105.0 104.9 104.7 104.9 
9 157.6 157.5 157.2 157.4 157.3 157.6 157.7 157.5 
10 105.7 105.7 105.6 105.7 105.6 105.8 105.7 105.7 





















118.4 127.7 149.6 (d, 
246.4) 








160.1 114.2 147.9 (d, 
10.2) 









113.9 159.9 124.5 (d, 
4.9) 








130.0 114.2 113.4 (d, 
1.6) 








111.9 127.7 118.3 (d, 
2.6) 
1''# 116.4 116.3 116.3 116.3 116.2 116.5 116.5 116.4 
2'' 126.4 126.9 126.9 126.5 126.6 126.5 126.3 126.5 
3'' 78.1 78.1 78.1 78.1 78.1 78.1 78.0 78.1 
4''† 28.6 28.6 28.6 28.6 28.7 28.7 28.6 28.7 
5''† 28.4 28.4 28.4 28.4 28.4 28.4 28.4 28.4 
1'''# 116.0 116.0 116.0 116.0 115.9 116.0 116.0 116.0 
2''' 126.8 126.5 126.6 126.8 126.9 126.8 126.7 126.9 
3''' 77.9 78.0 78.0 77.9 78.0 77.9 77.9 77.9 
4'''† 28.3 28.3 28.3 28.3 28.3 28.3 28.3 28.3 
5'''† 28.1 28.1 28.0 28.1 28.1 28.1 28.0 28.1 
OCH3 - - - - - 55.4 55.5 56.5 
 
* NMR frequency at 600 MHz; # and † indicate resonances that can be interchanged. 
 
Single crystal X-ray diffraction analysis 
A cube-shaped single crystal was selected and glued onto the tip of a glass fibre and mounted 
in a stream of cold nitrogen at 100(1) K and centred in the X-ray beam using a video camera.  
The crystal evaluation and data collection were performed on a Bruker Smart APEXII 
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diffractometer with Mo Kα radiation (λ = 0.71073 Å).  The diffractometer to crystal distance 
was set at 4.00 cm.  The initial cell matrix was obtained from three series of scans at different 
starting angles.  Each series consisted of 12 frames collected at intervals of 0.5º in a 6º range 
with the exposure time of 10 seconds per frame.  The reflections were successfully indexed 
by an automated indexing routine built in the APEXII program suite.  The final cell constants 
were calculated from a set of 6460 strong reflections from the actual data collection.  Data 
collection method involved ω scans of width 0.5°.  Data reduction was carried out using the 
program SAINT+.  The structure was solved by direct methods using SHELXS and refined.  
Non-H atoms were first refined isotropically and then by anisotropic refinement with full-
matrix least-squares calculations based on F2 using SHELXS.  All H atoms were positioned 
geometrically and allowed to ride on their respective parent atoms.  All H atoms were refined 
isotropically.  The absorption correction was based on fitting a function to the empirical 
transmission surface as sampled by multiple equivalent measurements.  The final least-
squares refinement of 286 parameters against 5126 data resulted in residuals R (based on F2 
for I≥2σ) and wR (based on F2 for all data) of 0.0404 and 0.1035, respectively.  The final 
difference Fourier map was featureless.  The programs Olex-2 and Ortep-3 were used within 
the WinGX software package to prepare artwork representation.  The molecular diagram is 
drawn with 50% probability ellipsoids. 
 
Results and Discussion  
The full characterisation (1H and 13C NMR assignments) of the pyranochromene chalcones 
3a-h and flavanones 4a-h are presented in Table 2-1 to Table 2-4 and the 1H spectra of a 
representative fluorinated chalcone and fluorinated flavanone is presented in Figure 2-1 and 
Figure 2-2.  The spectra of these compounds were well resolved.  With the aid of HSQC, 
HMBC, COSY and NOESY data as well as multiplicity patterns, the unambiguous chemical 




Figure 2-1  1H NMR spectrum of 2'-fluoropyranochromene chalcone (3b)  
 
For the pyranochromene chalcones, typical 1H and 13C NMR resonances can be observed for 
the pyran rings and the α,β-unsaturated ketone moiety.  Taking the 2-fluoro derivative (3b) 
as an example, the double bond of the α,β-unsaturated ketone moiety occurs as a distinct pair 
of doublets at δ 8.23 (H-7) and 7.83 (H-8) with a coupling constant of 15.9 Hz, typical of 
trans olefinic protons (Figure 2-1).  The carbonyl resonance (C-9) is distinctly separated 
from the other carbon resonances at δ 193.1 and shows HMBC correlations to both H-7 and 
H-8 (Figure 2-3), confirming the assignments of the α,β-unsaturated ketone moiety.  Due to 
conjugation between the double bond and the carbonyl group, C-8 (δC 130.5) is more 
shielded than C-7 (δC 135.4) and is therefore assigned further upfield than C-7.  This is 
however not the case for H-7 and H-8 and HSQC correlations show that H-8 appears more 
deshielded than H-7.  A 3J correlation in the HMBC spectrum can also be observed between 
H-7 and C-2 and C-6, verifying the assignment of H-7.  The H-8 resonance is more 
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deshielded due to the through space deshielding effect of the oxygen on the nearby pyran 
ring.   
 
 
Figure 2-2  1H NMR spectrum of 2'-fluoropyranochromene flavanone (4b) 
 
 
Figure 2-3  HMBC correlations of compound 3b, the 2-fluoropyranochromene chalcone 
 
There are four resonances between 7.10 and 7.60.  These are attributed to the aromatic proton 
resonances of the fluorinated aromatic ring B.  C-7 shows a HMBC correlation to the doublet 
of triplets (dt) at δH 7.57 (H-6).  This doublet of triplets arises from the coalescing of the 
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doublet of doublet of doublets (ddd) brought about by coupling with the fluorine atom and H-
5 (JH6, F = JH6,H5 = 7.6 Hz) and the meta coupling with H-4 (JH4,H6 = 1.4 Hz).  The H-6 proton 
resonance shows a COSY correlation to another triplet also arising because of coalescing of 
the doublet doublet that arises by coupling with both H-6 and H-4 with JH6,H5 = JH5,H4 = 7.5 
Hz.  No meta coupling between H-5 and H-3 is observed.  The other two aromatic resonances 
at δH 7.32-7.36 (m) and δH 7.12 (dd, J = 11.0, 8.8 Hz) were assigned to H-4 and H-3 
respectively and could be distinguished by HMBC correlations between C-1 (d, J = 11.4 Hz) 
and H-3.  C-1 also showed HMBC correlations to H-5.  JH3,F (11.0 Hz) was larger than JH3,H4 
(8.8 Hz).  The C-3 carbon resonance was identified by an HSQC correlation with H-3 and 
was seen overlapping with C-1''' and C-1'' as a doublet at δC 116.5 (J = 21.9 Hz).  C-4, C-5 
and C-6 were all identified similarly at δC 131.4 (d, J = 8.8 Hz, meta C-F coupling), 124.7 (d, 
J = 3.6 Hz, para C-F coupling) and 130.5 (d, J = 8.3 Hz, meta C-F coupling) respectively.  
The fluorine bonded C-2 showed HMBC correlations with H-7, H-6, H-4 and H-3 and was 
identified as a large doublet at δC 162.0 (J = 252.5 Hz). 
 
For the two pyran rings on the A ring (closer to the ketone), the H-2''/2''' resonances overlap 
as a pair of doublets, with four peaks for the two doublet resonances, the first and the third 
peak being assigned to H-2'' and the second and fourth peak being assigned to H-2'''. These 
doublets occur at δH 5.48 and δH 5.47 and have coupling constants of 10.0 Hz, characteristic 
of cis olefinic protons and can be interchanged.  The H-1'' and H-1''' proton resonances, 
although occurring close to each other do not overlap and can be distinguished as two 
separate resonances at δH 6.60 and δH 6.69 (J = 10.0 Hz).  The H-1'' and H-2'', and H-1''' and 
H-2''' resonances show clear coupling in the COSY spectrum.  Both H-2''' and H-2'' show 
HMBC correlations to C-3' and C-5' respectively at δC 102.80 and δC 102.76.  However, both 
these sets of resonances can be interchanged as they occur so close to each other that it is 
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difficult to tell them apart.  The H-1''' resonance was distinguished from the H-1'' resonance 
by a HMBC correlation between H-1''' and C-2' at δC 161.8.  The identification of H-1''' and 
H-1'' allowed the unambiguous assignments of C-4' (through an HMBC with H-1''') and C-6' 
(HMBC with H-1'').  The C-1' resonance at δC 106.17 was detected by a HMBC correlation to 
the 2'-hydroxy resonance at δH 14.36. 
 
The corresponding carbon resonances of H-1''' and H-1'' was found at δC 116.4 (C-1''') and δC 
116.7 (C-1'') in the HSQC spectrum.  There are two methyl proton resonances for the four 
methyl groups since the methyl groups on each of the pyran rings are equivalent due to the 
planar nature of the molecule.  Thus, H-4''/5'' occurs at δ 1.54 and H-4'''/5''' occurs at δ 1.46.  
These methyl resonances show HMBC correlations to C-2''/C-2''' and C-3'' and C-3''', the 
latter two carbon resonances occuring at δC 78.7 and 78.6, which can be interchanged.  The 
C-4''/5'' and C-4'''/5''' resonances occur at δC 28.6 and δC 28.1.  The HMBC correlations of 3b 
are reflected in Figure 2-3. 
 
A crystal structure of 3b (Figure 2-4) was solved in the monoclinic space group P21/c, with 
one molecule in the asymmetric unit.  The bond length and angles are in agreement with the 
expected average values for related compounds [21, 22].  The trans double bond is clearly 
evident for C-7 and C-8 and the 2'-hydroxy group is on the same side of the carbonyl group 
with weak intramolecular hydrogen bonds being experienced by the 2'-hydroxy and C-9 
carbonyl group.  Each of the methyl groups on a particular pyran ring is in a similar chemical 
environment being on different sides of the planar molecule.  The fluorine atom is seen 
pointing toward the angular pyran ring.  Both pyranochromene rings exist in a half chair 
conformation with Φ = 0.3779 (11) Å, θ = 112.14 (18)°, Ψ = 219.32 (19)°and Φ = 0.3460 
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(11) Å, θ = 113.85 (18)° and Ψ = 146.4 (2)° respectively.  This is similar to our previous 
reports on similar structures [21, 22]. 
 
 
Figure 2-4  ORTEP diagram of 3b 
 
The cyclisation of the chalcones to the flavanones is carried out with sodium acetate under 
reflux at 80 ºC in ethanol.  The spectra of the flavanones using 4b as an example (Figure 
2-2), is typified by a doublet doublet at δH 5.69 (H-2) deshielded by the oxygen and two 
double doublets at δH 2.93 (H-3a) and 2.81(H-3b) respectively.  The two protons at C-3 and 
the one proton at C-2 all couple with each other with JH-3a,H-3b = 16.6 Hz, JH-3a,H-2 = 3.2 Hz 
and JH-3b,H-2 = 12.9 Hz.  These coupling constants indicate that the H-2/H-3a dihedral angle is 
closer to 90º and the H-2/H-3b dihedral angle closer to 180º.  These occurrences take place 
with the concomitant disappearance of the distinctive H-7 and H-8 pair of doublets discussed 
above. 
 
Interestingly enough, the change in structure from the pyranochromene chalcone to the 
flavanone led to differences in the NMR resonances of the pyran rings.  In particular, whereas 
H-2'' and H-2''' overlapped in the chalcones and H-1'' and H-1''' could clearly be 
distinguished, the opposite now occurs with the flavanones.  As with the H-2''/H-2''' 
41 
 
resonances above the H-1''/H-1''' resonances appear as a series of four peaks, the first and the 
third being the doublet of H-1'' and the second and the fourth being the doublet of H-1'''.  
These occur at δH 6.58 and δH 6.57 respectively with JH-1'',2'' = 10.0 Hz and JH-1''',2''' = 9.9 Hz.  
These coupling constants were used to distinguish the olefinic methine resonances on each of 
the rings.   
 
Unlike in the chalcones where there was a clear correlation between H-1''' and C-2' which 
allowed us to assign each of the pyran ring resonances unambiguously, there is no correlation 
between H-1''' and C-9 in the flavanones to make this distinction.  Therefore each of the 
pyran ring resonances as well as C-5 and C-7, and C-6 and C-8 may be interchangeable.  
Nevertheless, H-1'' shows a HMBC correlation to C-6 and H-1''' a HMBC correlation to C-8.  
Since the planarity of the molecule changes in forming the flavanone, each of the methyl 
resonances in both the 1H and 13C NMR spectra appear as separate resonances at δH 1.52, 
1.50, 1.46 and 1.44, and δC 28.7, 28.4, 28.3 and 28.1.  However, it is impossible to assign any 
one of these resonances to a specific methyl group and these resonances are interchangeable.  
The chemical shifts and splitting patterns of the fluorinated aromatic ring of 4b were very 
similar to that of the chalcone 3b. 
 
The crystal structure of a related flavanone 4g (Figure 2-5) with a para methoxy group on 
the phenyl ring shows the absolute stereochemistry to be in the S configuration at C-2.  The 
dihedral angle between the axial H-2 and the axial H-3b is 137.8 (4)º, whereas the dihedral 
angle between the axial H-2 and the equatorial H-3a is 94.8 (3)º which explains the coupling 
constants above.  Both the pyran rings are now in an angular position with the phenyl ring 
being out of the plane of the benzopyranone ring with the dihedral angle between the least-
squares plane of the pyranochromene ring system and the phenyl ring being 40.65 (19)°.   
42 
 
The flavanone core ring exists in the half chair conformation (Φ = 0.453 (5) Å, θ = 53.8 (6)° 
and Ψ = 284.5 (7)°.   
 
 
Figure 2-5  ORTEP diagram of 4g 
 
Conclusion 
A series of pyranochromene chalcones and flavanones were synthesized and characterized by 
1D and 2D NMR spectroscopy and X-ray crystallography.  The stereochemistry of C-2 for 4g 
was shown to be in the S configuration for the flavanones and since the NMR spectra of all 
the other compounds prepared with the same method are similar, the series of compounds is 
deduced to have the S-configuration for C-2.  The 1H and 13C NMR assignments of the 
pyranochromene chalcones and flavanones were made with the aid of HSQC and HMBC data 
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Chapter 3. The synthesis and structural elucidation of novel 
pyranochromene chalcones and flavanones  
 
Abstract 
Chloro, bromo, nitro and naphthyl pyranochromene chalcones and their corresponding 
flavanones were synthesized and characterized by NMR spectroscopy and X-ray 
crystallography.  The E configuration of chalcone 3a and the S configuration of C-2 in 4c 
were determined by single crystal X-Ray diffraction.  The 1H and 13C NMR resonances of the 
synthesized compounds were unambiguously assigned.   
 
Keywords 






Pyranoflavonoids, a rare class of flavonoids characterised by the presence of a 2,2-dimethyl-
2H-pyrano moiety, have been widely investigated in recent years due to their interesting 
pharmacological properties [1-8].  These pyran groups on the flavonoid core skeleton 
increase the lipophilicity of these molecules, a desirable property for pharmaceutical 
compounds as lipophilic compounds have strong affinity to biological membranes [9].  A 
wide variety of chalcones and flavanones have been isolated from natural sources, however 
the prenylated chalcones and flavonoids are not as common as their hydroxy and methoxy 
counterparts.  
The synthesis of pyranoflavonoids has been reported with several methods [10-18].  An 
attractive and simple method is a three step route in which the hydroxylated benzaldehydes or 
acetophenone precursors are first reacted with 3-methyl-2-butenal to form the pyrano 
benzaldehydes or acetophenones and then condensed to form the 2'-hydroxychalcones and 
finally cyclised to the flavanones [10, 14, 18].  It is essential that the ortho hydroxy group of 
the acetophenone is left unreacted as this is used to form the flavanones.  Pyran rings can be 
inserted into hydroxylated acetophenones using prenyl bromide to first prenylate the 
acetophenone followed by cyclisation with DDQ [10, 12, 14], or in one step using 3-chloro-
3-methylbut-1-yne, CuI and acetone [15], or β-methyl crotonaldehyde (3-methyl-2-butenal) 
and ethylene diamine diacetate (EDDA) [13] or β-methyl crotonaldehyde and pyridine [11].   
Chalcone synthesis involves the Claisen-Schmidt condensation between acetophenones and 
benzaldehydes in aqueous alkaline bases [19]. Subsequent cyclization of 2'-hydroxychalcone 
intermediates lead to pyranoflavanones.  This can be done with either I2 and DMSO to 
produce flavones [10] or with sodium acetate and ethanol to produce flavanones [14]. We 
have recently reported the synthesis and structural elucidation of a series of fluorinated and 
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methoxylated pyranochalcones and flavanones [18].  We have used similar chemistry to 
provide novel chloro, bromo, nitro and naphthalene derivatives of pyranochromene chalcones 
and flavonoids.  Herein we report the synthesis and characterization of these molecules by 
NMR and X-ray crystallography.  
 
Experimental 
General Experimental Procedures   
Reagents and chemicals used in this study were purchased from Sigma Aldrich via Capital 
Lab, South Africa and were reagent grade.  All organic solvents were redistilled and dried 
according to standard procedures.  Optical rotations were recorded using a PerkinElmerTM, 
Model 341 Polarimeter with a 10 cm flow tube.  Melting points were measured using a Stuart 
Scientific Melting Point Apparatus SMP3.  IR spectra were recorded on a Perkin Elmer 
Spectrum 100 FT-IR spectrometer with universal ATR sampling accessory.  High-resolution 
mass data was obtained using a Bruker microTOF-Q II ESI instrument operating at ambient 
temperatures, with a sample concentration of approximately 1 ppm.  Thin layer 
chromatography (TLC) was performed using Merck Kieselgel 60 F254 plates.  Crude 
compounds were purified with column chromatography using silica gel (60–120 mesh) as the 
stationary phase and varying combinations of solvents depending on the sample to be 
purified.   
 
1H and 13C NMR spectra were recorded at 298 K with 5-10 mg samples dissolved in 0.5 mL 
of CDCl3 in 5 mm NMR tubes using a Bruker Avance
III 400 and 600 MHz NMR 
spectrometer (9.4 T; Bruker, Germany) (400.22 and 600.00 MHz for 1H, 100.63 and 150.00 
MHz for 13C and 376.58 Hz for 19F).  Chemical shifts (δ) are reported in ppm and coupling 
constants (J) in Hz.  The 1H and 13C NMR chemical shifts of the deuterated solvent were 7.24 
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and 77.0 respectively, referenced to the internal standard, TMS.  For the 19F NMR spectra, 
the chemical shift of trifluorotoluene (TFT) (0.05% in CDCl3) was referenced at -62.73.     
 
General procedure for the synthesis of the pyranochromene intermediate, 
octandrenolone (2) 
Using our previous method [11], 2,4,6-trihydroxyacetophenone (4.0 g, 0.0238 mol) was 
dissolved in pyridine (2.70 g) in a round bottom flask and 3-methyl-2-butenal (8.0 g, 0.0952 
mol) then added before heating the reaction to 110° C for 24 h.  The reaction was monitored 
by TLC using EtOAc:hexane (5:95, Rf = 0.6). On completion, HCl (30 ml) was used to 
neutralize the reaction and the organic portion extracted with ethyl acetate (4 × 40 ml).  The 
combined organic layer was dried over MgSO4 and the solvent removed under reduced 
pressure. The residue was purified by column chromatography on silica gel using 100% 
hexane to afford octandrenolone (1-(5-hydroxy-2,2,8,8-tetramethyl-2H,8H-pyrano[2,3-
f]chromen-6-yl)ethanone) (2) as a yellow crystalline solid (70.6% yield) with a melting point 
of 89–90 °C. 
1H NMR (400 MHz, CDCl3): δ 13.99 (1H, s, OH), 6.65 (1H, d, J = 10.1 Hz), 6.58 (1H, d, J = 
10.1 Hz), 5.45 (1H, d, J = 10.1 Hz), 5.43 (1H, d, J = 10.1 Hz), 2.65 (3H, s), 1.49 (6H, s), 1.43 
(6H, s).  13C NMR (100 MHz, CDCl3): δ 203.2, 160.5, 156.6, 154.9, 125.3, 124.6, 116.4, 
116.1, 105.7, 102.2, 102.1, 78.2, 78.1, 33.1, 28.5, 28.2. 
 
General procedure for the synthesis of pyranochromene chalcones 3a – 3e 
The chalcones were prepared according to our previously developed method [17] as outlined 
in Scheme 3-1.  To a solution of octandrenolone (2) (150 mg, 0.500 mmol) in ethanol (10 
mL) and water (2 mL), the substituted benzaldehydes (84.3 mg, 0.700 mmol) were added at 
room temperature with KOH (112 mg, 2.00 mmol).  The reaction mixture was stirred for 24 – 
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48 h at room temperature and monitored by TLC using EtOAc:hexane (10:90, Rf = 0.4). The 
solvent was distilled off under reduced pressure and the residue was dissolved in water (20 
mL) and made neutral with 2 M HCl (20 mL).  The organic portion was extracted with ethyl 
acetate (3 × 30 mL), washed with water and dried over anhydrous MgSO4.  Removal of the 
solvent followed by flash column chromatography on silica gel gave the pure compounds 3a-
e as brown solids.  1H and 13C NMR data for 3a-e are reported in Table 3-1 and Table 3-2.  
 
3-(2-Chlorophenyl)-1-(5-hydroxy-2,2,8,8-tetramethyl-2H,8H-pyrano[2,3-f]chromen-6-yl)-
propenone (3a) brown solid; Yield 90%; mp 114-115 oC;  Rf = 0.5 (EtOAc:hexane, 10:90); 
IR υmax 2972, 1625, 1583, 1467 cm




propenone (3b) brown solid; Yield 90%; mp 138-139 oC; Rf = 0.5 (EtOAc:hexane, 10:90); IR 
υmax 2974, 2935, 1629, 1603, 1583, 1543, 1461 cm
-1; HRESIMS m/z = 445.1182 [M+Na]+ 
(calcd. for C25H23O4ClNa 445.1183). 
 
3-(4-Bromophenyl)-1-(5-hydroxy-2,2,8,8-tetramethyl-2H,8H-pyrano[2,3-f]chromen-6-yl)-
propenone (3c) brown solid; Yield 85%; mp 140-141 oC; Rf = 0.5 (EtOAc:hexane, 10:90); IR 
υmax 2973, 2962, 2934, 1629, 1603, 1583, 1544, 1418 cm
-1; HRESIMS m/z = 489.0677 
[M+Na]+ (calcd. for C25H23O4BrNa 489.0677). 
 
3-naphthalen-2-yl-1-(5-hydroxy-2,2,8,8-tetramethyl-2H,8H-pyrano[2,3-f]chromen-6-yl)- 
propenone (3d) brown solid; Yield 68%; mp 134-135 oC; Rf = 0.5 (EtOAc:hexane, 10:80); IR 
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υmax 2956, 1626, 1578, 1543 cm




propenone (3e) brown solid; Yield 90%; mp 193-194 oC; Rf = 0.6 (EtOAc:hexane, 20:80); IR 
υmax 2971, 2925, 1634, 1580, 1530, 1457 cm
-1; HRESIMS m/z = 456.1424 [M+Na]+ (calcd. 
for C25H23NO6Na 456.1423). 
 
General procedure for the synthesis of pyranochromene flavanones 4a-4e 
Pyranochromene chalcones 3a-e (0.3 mmol) were added to a solution of sodium acetate (188 
mg, 3.0 mmol) in ethanol (10 mL) at room temperature and refluxed for 48 h at 80 °C.  Upon 
completion, the solvent was removed under reduced pressure and the residue dissolved in 
water (20 mL), acidifed with 2 M HCl (20 mL) and the organic portion extracted with ethyl 
acetate (3 × 30 mL), washed with water and dried over anhydrous MgSO4.  Removal of the 
solvent followed by flash column chromatography on silica gel afforded the pure 
pyranochromene flavanones 4a-e as yellow solids.  The 1H and 13C NMR data of 4a-e are 
reported in Table 3-3 and Table 3-4. 
 
2-(2-Chlorophenyl)-6,6,10,10-tetramethyl-2,3-dihydro-6H,10H-dipyrano[2,3-f;2',3'-
h]chromen-4-one (4a) yellow solid; Yield 36%; mp 130-131 oC; Rf = 0.5 (EtOAc:hexane, 
20:80); IR υmax cm
-1 2970, 2924, 1678, 1636, 1591, 1571, 1431 cm-1; HRESIMS m/z = 
445.1179 [M+Na]+ (calcd. for C25H23O4ClNa 445.1183). 
 
2-(4-Chlorophenyl)-6,6,10,10-tetramethyl-2,3-dihydro-6H,10H-dipyrano[2,3-f;2',3'-
h]chromen-4-one (4b) yellow solid; Yield 45%; mp 135-136 oC; Rf = 0.5 (EtOAc:hexane, 
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20:80); IR υ max 2975, 2925, 1682, 1636, 1571, 1438 cm
-1; HRESIMS m/z = 445.1178 
[M+Na]+ (calcd. for C25H23O4ClNa 445.1183). 
 
2-(4-Bromophenyl)-6,6,10,10-tetramethyl-2,3-dihydro-6H,10H-dipyrano[2,3-f;2',3'-
h]chromen-4-one (4c) yellow solid; Yield 50%; mp 171-172 oC; Rf = 0.5 (EtOAc:hexane, 
20:80); IR υmax 2977, 2960, 1683, 1666, 1638, 1591, 1572, 1412 cm
-1; HRESIMS m/z = 
489.0684 [M+Na]+ (calcd. for C25H23O4BrNa 489.0677). 
 
2-(Naphthalen-2-yl)-6,6,10,10-tetramethyl-2,3-dihydro-6H,10H-dipyrano[2,3-f;2',3'-
h]chromen-4-one (4d) yellow solid; Yield 43%; mp 161-162 oC; Rf = 0.5 (EtOAc:hexane, 
20:80); IR υmax 2925, 1671, 1634, 1574, 1432 cm
-1; HRESIMS m/z = 461.1729 [M+Na]+ 
(calcd. for C29H26O4Na 461.1729). 
 
2-(3-Nitrophenyl)-6,6,10,10-tetramethyl-2,3-dihydro-6H,10H-dipyrano[2,3-f;2',3'-
h]chromen-4-one (4e) yellow solid; Yield 38%; mp 107-108 oC; Rf = 0.5 (EtOAc:hexane, 
10:80); IR υmax 2969, 2923, 2853, 1684, 1639, 1591, 1570, 1526, 1429 cm
-1; HRESIMS m/z 
= 456.1418 [M+Na]+ (calcd. for C25H23NO6Na 456.1423). 
 
Synthesis of the 4-nitrophenyl pyranochromene flavone (5) 
4-Nitrobenzaldehyde (105 mg, 0.7 mmol) and potassium hydroxide (112 mg, 2.0 mmol) were 
added to a solution of octandrenolone (150 mg, 0.5 mmol) in ethanol (10 mL) and water (2 
mL) and stirred for 2 h at room temperature.  The product precipitated out of the reaction 
mixture.  It was then filtered, washed with cold ethanol and dried under vaccum, yielding the 
pure compound 2-(4-nitrophenyl)-6,6,10,10-tetramethyl-6H,10H-dipyrano[2,3-f;2',3'-
h]chromen-4-one (5) (149 mg, 70% yield) as a yellow solid with a melting point of 270-271 
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°C; IR υmax 2967, 2926, 1700, 1669, 1633, 1613, 1582, 1506 cm
-1; HRESIMS m/z = 
454.1269 [M+Na]+ (calcd. for C25H21NO6Na 454.1267). 
1H and 13C NMR data of 5 are 
reported in Table 3-3 and Table 3-4. 
 
Single crystal X-ray diffraction analysis 
Cube-shaped single crystals of compounds 3a and 4c were selected and glued onto glass fibre 
tips and mounted in a stream of cold nitrogen at 173(1) K and centred in the X-ray beam 
using a video camera.  Crystal evaluation and data collection were performed on a Bruker 
Smart APEXII diffractometer with Mo Kα radiation (λ = 0.71073 Å).  The diffractometer to 
crystal distance was set at 4.00 cm.  The initial cell matrix was obtained from three series of 
scans at different starting angles.  Each series consisted of 12 frames collected at intervals of 
0.5º in a 6º range with the exposure time of 10 seconds per frame.  The reflections were 
successfully indexed by an automated indexing routine built in the APEXII program suite.  
The final cell constants were calculated from a set of 6460 strong reflections from the actual 
data collection.  Data collection method involved ω scans of width 0.5°.  Data reduction was 
carried out using the program SAINT+.  The structure was solved by direct methods using 
SHELXS and refined.  Non-H atoms were first refined isotropically and then by anisotropic 
refinement with full-matrix least-squares calculations based on F2 using SHELXS.  All H 
atoms were positioned geometrically and allowed to ride on their respective parent atoms.  
All H atoms were refined isotropically.  The absorption correction was based on fitting a 
function to the empirical transmission surface as sampled by multiple equivalent 
measurements.  The program ORTEP3 was used to prepare artwork representation.  The 
molecular diagrams are drawn with 50% probability ellipsoids.  Crystallographic data 
(excluding structure factors) for the structure in this paper has been deposited with the 
Cambridge Crystallographic Data Centre, CCDC, 12 Union Road, Cambridge CB21EZ, UK.  
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Copies of the data can be obtained free of charge on quoting the depository numbers CCDC-
1031442 (for 3a) and CCDC-1031443 (for 4c) (Fax: +44-1223-336-033; E-Mail: 
deposit@ccdc.cam.ac.uk, http://www.ccdc.cam.ac.uk). 
 
Results and Discussion  
The synthesis of pyranochromene flavanones involved three steps (Scheme 3-1), formation 
of the pyran rings with 2',4',6'-trihydroxyacetophenone, condensation with aldehydes to 
produce chalcones and cyclisation of the chalcones to flavanones.  3-Methyl-2-butenal was 
used as the prenylating agent, which forms pyran rings under basic conditions at high 
temperatures (110 °C) at the 2'- and 4'- positions of 2',4',6'-trihydroxyacetophenone.  Various 
substituted benzaldehydes were used to produce several chalcones and flavanones.  We had 
previously reported on the synthesis of fluorinated and methoxylated chalcones and 
flavanones of this type and herein report the chloro, bromo, nitro and naphthyl derivatives.   
 
Scheme 3-1  Synthetic scheme for the synthesis of pyranochromene flavanones 4a-e.  i) 3-
methyl-2-butenal, pyridine, 110°C, reflux; ii) substituted benzaldehydes, KOH, EtOH/H2O, 
rt; iii) NaOAc, EtOH, 80°C, reflux. 
 
The chalcone intermediates 3a-e, were synthesized in good yields of between 60-90%.  The 
overall yields obtained for the flavanones were moderate at between 35-50%. These yields 
were consistent with that reported for the fluoro and methoxy derivatives [18].  Interestingly, 
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the 4-nitrobenzaldehyde did not form the chalcone on condensation with octandrenolone (2), 
but rather formed the flavone (5) in one single step.  We were however able to form the 
chalcone intermediate 3e and the flavanone 4e with 3-nitrobenzaldehyde.  The structures of 
the compounds were determined with IR, 1H NMR, 13C NMR, and mass spectral data.  In 
addition, X-ray crystallography was carried out on 3a and 4c to see how the packing of the 
crystal with the larger chlorine atom compares to the corresponding fluoro chalcones and 
how the para bromine atom compares to the corresponding methoxy flavanone reported in 
Pawar et al. [18].   We also used the crystal structure to determine the configuration at C-2 in 
the flavanones and see whether or not this is consistent with the 2S configuration for the 
methoxy flavanone [18]. 
Formation of the pyranochromene chalcones were shown typically by the H-7 and H-8 1H 
NMR resonances of the α,β-unsaturated ketone moiety, which occurred at δ 8.15 (H-8) and 
8.06 (H-7) with JH7,H8 = 15.6 Hz for 3a (Table 3-1).  The 2'-hydroxy group occurred as a 
singlet at approximately δ 14.26 for all the chalcones 3a-e, with the exception of 3d 
(naphthyl chalcone), where it appeared at δ 14.43.  The two pyran rings were evident from 
the two pairs of doublets that were present at δ 6.61 and δ 5.48 (JH1'',H2'' = 10.0 Hz) and δ 6.69 
and δ 5.46 (JH1''',2''' = 10.0 Hz).  The carbonyl resonance appeared at δ 192-193 in the 
13C 
NMR spectrum and all carbon resonances for the dipyrano aromatic ring and α,β-conjugated 
system are consistent with that reported earlier [18].  These are tabulated in Table 3-2. 
55 
 
Table 3-1 1H NMR shifts of pyranochromene chalcones 3a – 3e (CDCl3, J in Hz) 
No. 3a$ 3b* 3c* 3d* 3e* 
OH 14.26 (s) 14.28 (s) 14.26 (s) 14.43 (s) 14.17 (s) 
1 - - - 8.00 (s) - 
2 - 7.51 (d, 8.3) 7.54 (d, 8.3) - 8.52(s),  
3 7.45 - 7.43 (m) 7.38 (d, 8.3) 7.45 (d, 8.3) 7.75 (dd, 8.2, 
0.9) 
- 
4 7.31 - 7.29 (m) - - 7.87 (d, 8.6) 8.22 (d, 7.9) 
5 7.31 - 7.29 (m) 7.38 (d, 8.3) 7.45 (d, 8.3) 7.87 (d, 8.6) 7.59 (t, 7.9) 
6 7.71 - 7.68 (m) 7.51 (d, 8.3) 7.54 (d, 8.3) 7.53 - 7.50 (m) 7.83 (d, 7.6) 
7 8.15 (d, 15.6) 7.68 (d, 15.7) 7.67 (d, 15.8) 7.53 - 7.50 (m) 7.73 (d, 15.6) 
8 8.06 (d, 15.6) 8.04 (d, 15.7) 8.06 (d, 15.8) 7.85 - 7.83(m) 8.23 (d, 15.6), 
11 - - - 7.93 (d, 15.7) - 
12 - - - 8.21 (d, 15.7) - 
1'' 6.61 (d, 10.0)  6.61 (d, 10.2) 6.61 (d, 10.1) 6.63 (d, 9.9) 6.61 (d, 9.8) 
2''# 5.48 (d, 10.0) 5.48 (d, 10.2) 5.48 (d, 10.1) 5.50 (d, 9.9) 5.50 (d, 9.8) 
4''/5''† 1.52 (s) 1.53 (s) 1.53 (s) 1.59 (s) 1.58 (s) 
1''' 6.69 (d, 10.0) 6.68 (d, 10.0) 6.68 (d, 9.8) 6.71 (d, 9.9) 6.68 (d, 10.1) 
2'''# 5.46 (d, 10.0) 5.47 (d, 10.0) 5.47 (d, 9.8) 5.49 (d, 9.9) 5.49 (d, 10.1) 
4'''/5'''† 1.46 (s) 1.46 (s) 1.46 (s) 1.47 (s) 1.46 (s) 




Table 3-2 13 C NMR shifts of pyranochromene chalcones 3a – 3e (CDCl3) 
No. 3a$ 3b* 3c* 3d* 3e* 
1 134.1 134.4 124.4 130.5 137.7 
2 135.7 129.5 132.4 134.4 121.8 
3 130.6 129.4 129.7 123.8 148.9 
4 127.2 136.1 134.8 128.9 124.3 
5 130.9 129.4 129.7 128.8 130.2 
6 127.5 129.5 132.4 127.3 134.6 
7 137.8 140.6 140.7 126.9 138.7 
8 130.2 128.4 128.5 128.0 130.7 
9 192.8 192.8 192.8 133.4 192.2 
10 - - - 133.7 - 
11 - - - 142.3 - 
12 - - - 128.1 - 
13 - - - 193.0 - 
1' 106.2 106.1 106.1 106.2 106.1 
2' 161.7 161.3 161.6 161.7 161.7 
3' 102.9 102.8 102.8 102.9 102.9 
4' 155.7 155.7 155.7 155.5 156.0 
5' 102.7 102.8 102.8 102.8 102.8 
6' 156.4 156.4 156.4 156.4 156.5 
1'' 116.8 116.8 116.8 116.8 116.7 
2'' 125.6 125.7 125.7 125.6 125.8 
3'' 78.6 78.6 78.6 78.6 78.9 
4''/5'' 28.6 28.6 28.6 28.6 28.7 
1''' 116.4 116.4 116.4 116.5 116.3 
2''' 124.9 125.0 125.0 125.0 125.1 
3''' 78.5 78.5 78.5 78.5 78.8 
4'''/5''' 28.3 28.3 28.3 28.3 28.3 
$ 400 MHz; * NMR at 600 MHz 
 
The chalcones 3a-e were cyclized to the flavanones 4a-e with sodium acetate and were 
confirmed to have occurred due to the disappearance of the ∆7 trans double bond and the 
appearance of an ABX system for the H-2 and two methylene H-3 resonances. For instance in 
4b, H-2, H-3a and H-3b occurred as double doublets at δ 5.37, δ 2.75 and δ 2.91 with JH2,H3a 
= 2.9 Hz, JH2,H3b = 13.0 Hz and JH3a,H3b = 16.5 Hz, consistent with our previous set of 
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flavanones [18].  An exception was 4a, the 2-chloro derivative, where H-2/H-3b coupling 
was not observed.  In this instance H-2 appeared as a doublet at δ 5.75 (J = 13.1 Hz) and H-
3a and H-3b appeared at δ 2.77 (dd, J = 16.6, 13.1 Hz) and δ 2.91 (d, J = 16.6 Hz) 
respectively.  This peculiarity was not observed in the fluoro and methoxy derivatives and is 
specific to the 2-chloro derivative [18].  The NMR data for 4a-e are tabulated in Table 3-3 
and Table 3-4. 
 
The position of the substituents on the phenyl ring of flavanones affect the H-2 resonance.  
With ortho positioned substituents such as 2-chloropyranochromene flavanone 4a, H-2 is the 
most deshielded occurring at δ 5.75 and becoming more shielded as the substituent moves to 
the 3-position (δ 5.48 in the 3-nitro derivative 4e) and the 4-position (δ 5.37 and δ 5.35 in 4b 
and 4c, respectively).  With the naphthyl group, H-2 appears at δ 5.56.  
  
In the pyran rings, all the resonances of the flavanones 4a-e are similar to that of the 
chalcones 3a-e, with the exception that the H-4'', H-5'', H-4''' and H-5''' resonances now 
appear as separate resonances.  For example δ 1.53 (H-4''), δ 1.50 (H-5''), δ 1.46 (H-4''') and δ 
1.44 (H-5''') in 4a appear as separate resonances, since the flavanone backbone is not as 






Table 3-3 1H NMR shifts of pyranochromene flavanones 4a – e and flavone 5 (CDCl3, J in 
Hz) 
No. 4a2 4b2 4c1 4d1 4e1 51 
2 5.75 (d, 13.1) 
5.37 (dd, 13.0, 
2.7) 
5.35 (dd, 13.0, 
2.9) 
5.56 (dd, 13.1, 
2.8) 




2.77 (dd, 16.6, 
13.1)5 
2.75 (dd, 16.5, 
2.7) 
2.75 (dd, 16.6, 
2.9) 
2.86 (dd, 16.5, 
2.8) 
2.75 (dd, 16.4, 
3.1) 
6.68 (s) 
3b 2.91 (d, 16.6) 
2.91 (dd, 16.5, 
13.0) 
2.90 (dd, 16.6, 
13.0) 
3.07 (dd, 16.5, 
13.1) 
2.93 (dd, 16.4, 
12.7) 
- 
1' - - - 7.91 (s) - - 
2' - 7.39 (s) 7.54 (d, 8.1) - 8.36 (s), 8.26 (d, 8.8) 
3' 
7.40 - 7.35 
(m) 
7.39 (s) 7.33 (d, 8.1) 
7.57 (dd, 8.5, 
1.7) 
- 7.95 (d, 8.8) 
4' 
7.40 - 7.35 
(m) 
- - 7.90 (d, 8.5 ) 8.22 (d, 7.9) - 
5' 
7.31 - 7.28 
(m) 
7.39 (s) 7.33 (d, 8.1) 
7.88 – 7.85 
(m) 
7.61 (t, 7.9) 7.95 (d, 8.8) 
6' 7.70 (d, 7.6) 7.39 (s) 7.54 (d, 8.1) 
7.53 - 7.50 
(m) 
7.76 (d, 7.7) 8.26 (d, 8.8) 
7' - - - 
7.53 - 7.50 
(m) 
- - 
8' - - - 
7.88 – 7.85 
(m)  
- - 
1'' 6.58 (d, 10.0)6 6.57 (d, 10.0) 6.56 (d, 10.1)7 6.58 (d, 10.2) 6.58 (d, 10.0) 6.56 (d, 10.1) 
2'' 5.47 (d, 10.0) 5.48 (d, 10.0) 5.48 (d, 10.1) 5.52 (d, 10.2) 5.51 (d, 10.0)4 5.66 (d, 10.0) 
4''3 1.53 (s) 1.52 (s) 1.52 (s) 1.54 (s) 1.52 (s) 1.54 (s) 
5''3 1.50 (s) 1.48 (s) 1.48 (s) 1.50 (s) 1.49 (s) 1.54 (s) 
1''' 6.58 (d, 10.0)6 6.56 (d, 10.0) 6.56 (d, 10.1)7 6.63 (d, 9.9) 6.57 (d, 9.9) 6.62 (d, 10.0) 
2''' 5.51 (d, 10.0) 5.51 (d, 10.0) 5.51 (d, 10.1) 5.48 (d, 9.9) 5.52 (d, 9.9) 5.53 (d, 10.0) 
4'''3 1.46 (s) 1.46 (s) 1.46 (s) 1.47 (s) 1.47 (s) 1.52 (s) 
5'''3 1.44 (s) 1.44 (s) 1.44 (s) 1.45 (s) 1.46 (s) 1.52 (s) 
1 400 MHz; 2 NMR at 600 MHz; 3 indicate resonances that can be interchanged; 4 signals overlap; 5 due to 
coalescing of resonances, this appears as a triplet with J = 14.9 Hz; 6 1'' and 1'' coalesce and appear as a triplet; 




Table 3-4 13C NMR shifts of pyranochromene flavanones 4a-e and flavone 5 (CDCl3) 
No. 4a* 4b* 4c$ 4d* 4e$ 5$ 
2 76.3 78.5  78.5  78.0 78.0 139.6 
3 44.7 46.0 46.0 46.1 46.0 106.9 
4 188.6 188.5 188.3 188.8 187.6 179.8 
5 154.5 154.5 154.5 154.5 154.7 154.0 
6 102.6 102.5 102.5 102.6 102.6 99.2 
7 156.2 156.2 156.2 156.2 156.2 156.9 
8 105.0 105.0 105.0 104.9 105.2 105.7 
9 157.6 157.3 157.3 157.7 156.8 161.5 
10 105.7 105.7 105.7 105.8 105.6 106.9 
1' 137.2 134.5 122.6 125.3 141.5 147.3 
2' 132.0 129.1 132.1 136.7 121.2 131.4 
3' 129.9 126.6 127.8 128.8 148.8 124.1 
4' 127.5 137.8 138.4 124.0 123.6 150.1 
5' 129.6 126.6 127.8 128.0 130.0 124.1 
6' 127.2 129.1 132.1 126.8 132.0 131.4 
7' - - - 126.7 - - 
8' - - - 128.3 - - 
9' - - - 133.4 - - 
10' - - - 133.5 - - 
1'' 116.4 116.3 116.3 116.5 116.1 115.7 
2'' 126.6 127.5 126.6 126.6 127.1 127.9 
3'' 78.2 78.2 78.1 79.4 78.3 79.4 
4'' 28.7 28.7 28.7 28.7 28.7 28.7 
5'' 28.4 28.4 28.4 28.4 28.4 28.7 
1''' 116.0 116.0 116.0 116.1 115.9 114.5 
2''' 126.9 126.9 126.9 126.5 127.0 127.2 
3''' 78.0 78.0 78.0 78.1 78.2 79.3 
4''' 28.3 28.3 28.3 28.3 28.3 28.6 
5''' 28.1 28.1 28.1 28.1 28.1 28.6 
$ 400 MHz; * NMR at 600 MHz 
 
As expected, the major differences in the 1H and 13C NMR spectra compared to the fluoro 
and methoxy derivatives reported in Pawar et al. [18] were in the phenyl ring.  For the 2-
chloro dipyranochalcone derivative, the H-3 and H-6 resonances occurred separately as 
multiplets at δ 7.43-7.45 and δ 7.68-7.71, with H-4 and H-5 overlapping as a multiplet at δ 
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7.29-7.31.  On conversion to the flavanone, the resonances occurred at approximately the 
same chemical shift, but now H-6 was a distinct doublet at δ 7.70 (J = 7.6 Hz) and the H-3 
and H-4 resonances overlapped at δ 7.35-7.40, while H-5 appeared separately at δ 7.28-7.31 
as a multiplet.  As expected, a pair of doublets were seen for the 4-chloro chalcones 
derivative at δ 7.51 (H-2/6) and δ 7.38 (H-3/5) with J = 8.3 Hz.  The H-3/5 resonance was 
more shielded than H-2/6 due to the electron donating chloro substituent.  Interestingly, the 
H-7 resonance, which appeared at δ 8.15, now resonated at δ 7.68.  The more deshielded 
resonance in the 2-chloro derivative must be due to an interaction between H-7 and the 2-Cl 
substituent, which deshields H-7.  More interesting was the fact that upon cyclisation to the 
flavanone, the H-2/6 and H-3/5 resonances, both coalesced into one four-proton singlet 
resonance at δ 7.39.  This indicates that the –CH2CHO group (C-2) in the pyranone ring 
attached to C-1' has the same effect on H-2'/6' that the chloro group at C-4' has on C-3'/5'.   
The pair of doublets H-2/6 and H-3/5 for the 4-bromo chalcone derivatives were similar to 
that of the 4-chloro derivative appearing at δ 7.54 and δ 7.45 respectively with J = 8.3 Hz.  In 
the corresponding flavanone, the resonances did not coalesce into one as in the 4-chloro 
derivative, but H-3/5 was observed to be more shielded than in the chalcones.   
 
For the 3-nitro derivative, a typical 3-substituted pattern was seen for both the chalcone and 
flavanone derivatives with H-2 being present at δ 8.51 (s), H-4 at δ 8.22 (d, J = 7.9 Hz), H-5 
at δ 7.59 (t, J = 7.9 Hz) and H-6 at δ 7.83 (d, J = 7.6 Hz).  For the napthyl derivate of the 
chalcones, H-1 was a singlet at δ 8.00, H-3 at δ 7.75 (dd, J = 8.2, 0.9 Hz), H-4 and H-5 as an 
overlapping doublet at δ 7.87 (J = 8.6 Hz), H-6 and H-7 at δ 7.50-7.53 (occurring together as 
a multiplet) and H-8 as a multiplet at δ 7.83-7.85.  These resonances were very similar when 
the chalcone was cyclized to the flavanone, with the exception that the H-1 and H-3 
resonances were now more shielded at δ 7.91 (s) and δ 7.57 (dd, J = 8.5, 1.7 Hz) respectively. 
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The condensation of 4-nitrobenzaldehyde with octandrenolone resulted in the formation of 
the flavone (Scheme 3-2), without proceeding through the chalcone and flavanone 
intermediates, even on repeating the experiment.  This was quite surprising, but was 
confirmed by the 1H and 13C NMR spectra with the presence of the olefinic H-3 at δ 6.68 as a 
singlet and the olefininc C-2 and C-3 at δ 139.6 and δ 106.9 and the carbonyl C-4, which was 
more shielded than that of the flavanones at δ 179.8.  The 4-nitrophenyl ring was evident with 
a pair of doublets at δ 8.26 and δ 7.95 with an ortho coupled J value of 8.8 Hz.  The planarity 
of this flavone ring to the flavanone ring was also demonstrated by the fact that the two pairs 
of methyl groups, one on each of the two pyran rings were equivalent and hence two six-
proton methyl resonances, similar to the that present in the chalcones were seen at δ 1.54 (H-




Scheme 3-2  Reaction for the synthesis of the 4-nitropyranodichromene flavone 5.  i) 4-
nitrobenzaldehyde, KOH, EtOH/H2O, rt. 
 
Compound 3a (Figure 3-1) crystallizes in the monoclinic P21/c space group with one 
molecule in the asymmetric unit.  The molecular structure displays three fused rings 
composed of a phenol ring and two dimethyl substituted pyran rings.  These are linked to a 
chlorobenzene ring through a C(=O)—C=C  moiety whose C=C double bond is trans (torsion 
angle for H7-C7-C8-H8 = 177.5(2)°).  The plane of the phenol ring fused to the pyrans rings 
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and that of the chlorobenzene ring are coplanar with a small deviation of 3.8(3)°.  The 
C(=O)—C=C moiety, however, deviates from the two planes by an angle of 10.8(4) to the 
phenol ring  and 11.7(4)° to the chlorobenzene ring.  Both pyranochromene rings exist in a 
half chair conformation with Φ = 0.2456 (15) Å, θ = 63.7 (4)°, Ψ = 30.2 (4)°and Φ = 0.2966 
(15) Å, θ = 63.2 (3)° and Ψ = 26.3 (3)°, respectively.  Each of the methyl groups on their 
respective pyran rings are equivalent due to the planarity of the molecule.  All bond lengths 
and angles are in agreement with the expected average values for related compounds [11, 17].  
In addition to the O—H…O intramolecular hydrogen bond, the 2'-hydroxy and the carbonyl 
group experiences other weak intramolecular hydrogen bonds and π…π intermolecular 
interactions that stabilise the crystal lattice which compares well with our previous reports on 
similar structures [11, 17]. However, unlike the 2-fluoro derivative [18], where the fluorine 
and carbonyl groups were on different sides, the larger chlorine atoms in ring B is now on the 
same side of the carbonyl group.   
 
 
Figure 3-1  ORTEP diagram of 3a 
 
Compound 4c (Figure 3-2) crystallizes with two symmetrically unrelated molecules of 4-
bromo-dipryanoflavanone in the asymmetric unit.  Both molecules display a central 
essentially planar backbone composed of a phenyl ring that is fused to two pyran rings and a 
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pyranone ring attached to a bromobenzene ring through a chiral carbon.  The structure of 4c 
shows the absolute stereochemistry to be in the S configuration at this carbon (see C-2 of 4c 
in Scheme 3-1).  The planar backbone of the two molecules in the asymmetric unit are 
oriented parallel to each other (dihedral angle between the two phenyl groups = 7.6(2)°), with 
the benzophenyl moieties oriented differently in the two 38.8(10) in one and 85.7 (10)° in the 
second.  The dihedral angle between H-2 and the axial H-3b is 136.9 (3)°, whereas the 
dihedral angle between the H-2 and the equatorial H-3a is 90.2 (2)°.  These dihedral angles 
were similar to earlier results [18].  The flavanone core ring exists in the half chair 




Figure 3-2  ORTEP diagram of 4c 
 
Conclusion 
A series of novel pyranochromene chalcones and flavanones were synthesized and 
characterized by 2D NMR spectroscopy and X-ray crystallography.  The chalcones were 
converted to the flavanones with the 2S configuration.  Some interesting observations were 
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made.  The 4-nitrobenzaldehyde was converted straight to the flavone on condensation with 
the dipryanated acetophenone.  The 4-chloro flavanone derivative contained a single singlet 
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A series of pyranochromene chalcones 3a-m, flavanones 4a-m and flavone 5 with F, Cl, Br, 
OCH3, NO2 and naphthalene substituents on the B ring and two pyran rings fused to the A 
ring were tested for their antibacterial, antifungal and antioxidant activity.  Chalcones 3a, 3d, 
3i (unsubstituted, 4-F and 2-Cl derivatives) and flavanones 4a and 4i (unsubstituted and 2-Cl) 
displayed potent antibacterial activity, whereas chalcones 3a, 3b, 3d, 3l and 3m 
(unsubstituted, 2-F, 4-F, 3-NO2 and naphthalene derivatives) and flavanone 4b, 4d, 4f and 4l 
(2-F, 4-F, 3-OCH3 and 3-NO2 derivatives) exhibited moderate to significant antifungal 
activity.  In general, the pyranochromenes showed good antioxidant activity.   
Keywords: Pyranochromene chalcones, pyranochromene flavanones, antibacterial activity, 






Flavonoids are a group of common and naturally occurring polyphenolic compounds that are 
widely found in the plant kingdom.  Prenylated chalcones and flavanones are a unique class 
of naturally occurring flavonoids characterized by the presence of a prenylated side chain in 
the flavonoid skeleton.  Cyclisation of prenyl groups onto the aromatic ring result in 
chromene and pyranochromene compounds.  Prenyl and pyran groups increase the 
lipophilicity and consequently enhance their interaction with cellular membranes [1].  
Favorable properties and enhanced biological activities of halogens and hydroxyl functional 
groups were attributed to its dipole character, hydrogen bonding capability, rigidity and 
stability under in vivo conditions. 
 
Prenylated chalcones and flavanones are rapidly gaining importance in medicinal and 
synthetic chemistry due to their diverse biological properties. These include anticancer 
activity [2-4], tyrosine protein kinase inhibition [2], antileishmanial activity [5], protein 
kinase C inhibition for the treatment of neurological or inflammatory responses [6], anti-
inflammatory activity [7] and as trypanosomal glyceraldehyde-3-phosphate dehydrogenase 
inhibitors [8].  Paul and Choudhury [9-10] reported molecular docking studies of 
Pongachalcone I, which exhibited potent inhibitory activity against the multidrug resistant 
bacterium Pseudomonas putida. 
 
This work forms part of an ongoing study on the synthesis of biologically active 
pyranochromene compounds and presents the antimicrobial and antioxidant evaluations of 
synthesized pyranochromene chalcones and flavanones.  There is always a need for new 
antibiotics due to the growing problem of antibiotic resistance [11].  This paper explores the 





The pyranochromene chalcones (3a-m) and flavanones (4a-m) (Figure 4-1) were previously 
prepared in our laboratory [12].  These molecules contained a pyranochromene skeleton on 
ring A and either an unsubstituted or F, Cl, Br, OCH3 and NO2 group at various positions on 
the phenyl ring or a naphthalene group instead of the phenyl ring.  Attempts to make the 
chalcones and flavanones with the 4-NO2 benzaldehyde did not yield the target molecules but 
the flavone (5) (Figure 3-1) instead.  This was also used for the bioassays. 
 
Antimicrobial assay 
Antifungal/antibacterial agents:  Stock solutions with a concentration of 2mM of the test 
compounds were prepared in DMSO and diluted before assays.  Amphotericin-B and 
neomycin purchased from Sigma Aldrich were used as reference drugs for the antifungal and 
antibacterial assays, respectively.  The final concentration of the synthesized compounds 
ranged from 0.0012 to 200 µg mL-1, amphotericin-B ranged from 0.0015 to 100 µg mL-1 and 
neomycin from 0.0076 to 500 µg mL-1.  All drug dilutions were carried out in 96-well flat 
bottom microtitre plates.  The final concentration of DMSO in each well was 2 nM or 
0.001%. 
 
Antifungal susceptibility test:  Evaluation of the susceptibility of Candida albicans and 
non-Candida albicans species were performed using the broth micro dilution method 
according to M27-A2 for yeast guidelines.  Yeast strains were grown aerobically overnight at 
35 °C on Sabouraud dextrose agar plates.  Yeasts were harvested and suspended in 1% sterile 
saline and the turbidity of the supernatants measured using a spectrophotometer at 625 nm 
with an absorbance of 0.08-0.1 equivalents to a 0.5 McFarland standard following the 
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NCCLS M27-A2 guidelines.  The working suspension was diluted to 1:20 in a mixture 
containing RPMI 1640 medium and 0.165 M morpholinepropanesulfonic acid buffered to pH 
7.0.  The working suspension was further diluted with the medium (1:50) to obtain the final 
test inoculums (1-5×103 CFU mL-1).  The microtitre plates containing different concentrations 
of test compounds were allowed to thaw and equilibrate to room temperature under aseptic 
conditions. Aliquots of working inoculum suspensions were dispensed into each well and the 
plates incubated in an aerobic environment at 35 °C for 24 h.  After incubation, 20 µL of 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
salt (MTS, Promega Corporation, Madison, USA) was added to each well, incubated at 37 ºC 
for 4 h and the absorbance recorded at 490 nm on a 96-well plate reader (Biotek, Powerwave 
XS2).  All analyses were performed in triplicate and the data was found to be reproducible.  
The minimum inhibitory concentration (MIC) is the lowest concentration at which growth of 
the fungi was inhibited. 
 
Antibacterial susceptibility test:  Bacterial susceptibility tests were carried out using the 
micro broth dilution method.  Overnight cultures after 16-18 h of incubation at 37 ºC were 
adjusted to the turbidity of a 0.5 McFarland standard.  Inocula were adjusted to an absorbance 
of 0.08 - 0.10 to yield a stock suspension of 0.4-5×108 CFU mL-1, which was diluted one 
hundred fold to obtain a working suspension of 106 CFU mL-1 at 625 nm.  Microtitre plates 
were placed in a laminar flow unit to equilibrate to room temperature under aseptic 
conditions.  Aliquots of 100 µL of bacterial inoculate were added to the microtiter plates 
containing different concentrations of test compounds.  Plates were incubated aerobically for 
16-18 h at 37 °C.  Following incubation, 40 µL of freshly prepared iodonitrotetrazolium 
chloride [2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H tetrazolium chloride] (INT) 
solution (200 µg mL-1) was added to each well and the plate further incubated for 45 minutes 
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at 37 ºC in the dark.  If the colorless INT is reduced to red after incubation, persistent growth 
of bacteria is indicated.  No color change denotes the lack of bacterial growth.  Neomycin 
was used as a control drug in this study.  All analyses were performed in triplicate and the 
data was found to be reproducible.  The minimum inhibitory concentration (MIC) is the 
lowest concentration at which growth of the bacteria was inhibited. 
 
In vitro antioxidant studies 
All the newly synthesized compounds were screened for radical scavenging (antioxidant 
properties) on 2,2’-diphenly-1-picrylhydrazyl (DPPH) following the method by Burits and 
Bucar [13].  Various concentrations of the compounds were dissolved in methanol and 1 mL 
was added to 4 mL of a 0.004% solution of DPPH in methanol.  After a 30 min incubation 
period at room temperature, the absorbance was read against a blank (containing MeOH only) 
at 517 nm.  The percentage scavenging activity of free radicals by DPPH was calculated 
using the following equation: 
% scavenging activity = [(A control – A sample) / A blank] x 100. 
Where 'A control' is the absorbance of the control reaction (containing all reagents except the 
test compound) and 'A sample' is the absorbance of the reagents with a particular test 
compound.  The IC50 value was obtained by plotting a graph of concentration (in µg mL
-1) 
against % scavenging activity using Microsoft Excel. 
 
Results and Discussion 
Chemical structures 
The chemical structures of the compounds used in the structure activity relationship (SAR), 
have either a chalcone (3a-m) or flavanone (4a-m) backbone (Figure 4-1).  The chalcones 
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had a pyranochromene moiety, which was acetophenone derived.  The same moiety 
transformed into the flavanones resulting in three pyran rings surrounding the acetophenone 
derived benzene ring.  The aldehyde derived phenyl ring was either unsubstituted (3a/4a), 
monosubstituted, containing F at the ortho, meta or para positions (3b-d/4b-d), OCH3 at the 
meta or para positions (3f-g/4f-g), Cl at the ortho or para positions (3i-j/4i-j), Br at the para 
position (3k/4k) and NO2 at the meta position (3l/4l).  In addition, the disubstituted 
compounds, 2,4-difluoro (3e/4e) and 2-fluoro-3-methoxy (3h/4h) and the naphthalene 
derivative were also used.  The flavone (5) had the same backbone as the flavanones, but had 
a double bond at ∆2 and a para NO2 group on the phenyl ring. 
 
 





The compounds were evaluated for their in vitro antibacterial activity against Staphylococcus 
aureus, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae and Pseudomonas 
aeruginosa.  Table 4-1 summarizes the MIC results obtained for the active compounds 
against the five different bacterial species.  Four compounds showed a broad spectrum of 
activity, having antimicrobial activity against all the bacterial strains used in the assay.  These 
were the unsubstituted chalcone 3a, with MICs between 32.2 and128.7 µM, the unsubstituted 
flavanone 4a (MIC between 18.7 and 64.4 µM), the 4-OCH3 chalcone 3g (MICs between 
119.5 and 239.0 µM) and the 2-Cl flavanone 4i (MICs between 29.6 and 118.2 µM).  The 
best activity was shown by 4a, better than the acetophenone precursor (2), indicating that not 
only were the pyran rings on the flavanone nucleus important, but also the flavanone core 
skeleton.   
 
Table 4-1  MIC (µM) of test compounds on Gram positive and Gram negative bacterial 
strains 
MIC (µM) 
 Gram positive Gram negative 
Compounds* S. aureus E. faecalis E. coli K. pneumonia P. aeruginosa 
2 _ _ 83.2 166.5 166.5 
3a 32.2 32.2 32.2 128.7 128.7 
4a  32.2 18.7 32.2 64.4 64.4 
3b _ _ 123.0 _ _ 
4b _ _ 246.0 _ _ 
3d  61.5 _ 30.7 61.5 30.7 
3e _ _ 117.8 _ _ 
3g 239.0 119.5 239.0 119.5 119.5 
3i 29.6 _ 29.6 29.6 29.6 
4i 59.1 29.6 59.1 59.1 118.2 
4j _ 236.5 _ _ _ 
5 2.3 _ 463.6 46.3.6 463.6 
Neomycin 16.3 32.5 8.1 16.3 8.1 
* The following compounds had no activity against all the bacterial species and were omitted from the table:  
3c, 4c, 4d, 4e, 3f, 4f, 4g, 3h, 4h, 3j, 3k, 4k, 3l, 4l, 3m and 4m;  “-” indicates no activity 
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In general, the flavanone 4a had better activity than its chalcone precursor 3a, indicating that 
the pyranone nucleus in 4a contributed to better activity than the α,β-unsaturated moiety in 
3a.  The activity of the 2-Cl derivative 4i was not as good as the unsubstituted derivatives, 
being 2-fold less active than 3a and 4a in some of the bacterial strains.  The 4-OCH3 
derivative 3g in some cases showed a 8 fold decrease in activity compared to 3a and 4a.  
Compared to the neomycin control, 3a and 4a had a 2-fold decrease in activity with regard to 
S. aureus and 4a was 2-fold better than neomycin against E. faecalis.  The chalcone 3a had 
the same activity to that of neomycin against E. faecalis.  The 2-Cl chalcone 3i showed the 
best activity against the Gram negative strains, being active at 29.6 µM for all Gram negative 
strains and S. aureus.  Likewise, the 4-F chalcone 3d showed good activity, being active at 
30.7 µm for E.coli and P. aeruginosa and 61.5 µM against K. pneumonia and S. aureus.  
Both 3d and 3i were inactive against E. faecalis. 
 
The para NO2 flavone 5 showed excellent activity against S. areus at 2.3 µM, but did not 
show any activity against E. faecalis and very high MIC values against the Gram negative 
strains.  This was synthesized as a product of one of the reactions, where the target molecule 
was unable to be synthesized and hence a series of these flavones were not tested for 
comparison.  However, this could be an excellent lead for an antibiotic against S. aureus.   
 
Antifungal activity 
The same set of compounds were evaluated for their in vitro antifungal activity against four 
Candida species comprising C. albicans ATCC 90028, C. albicans ATCC 10231, C. krusei 
ATCC 6258, and C. parapsilosis ATCC 22019.  The results are reported in Table 4-2.  
Compounds 3a/4a, 3d/4d, 4f, 4l and 3m showed good activity against all four strains of fungi 
having MIC values of 28.5 to 64.4 µM.  Of these, only 3a had an MIC of 128.7 against C. 
74 
 
albicans ATCC 90028.  These compounds were either unsubstituted on the phenyl ring 
(3a/4a) or contained a 4-F (3d/4d), 3-OCH3 (4f), 3-NO2 (4l) or naphthalene group (3m) on 
the skeleton of the chalcone or flavanone.  In addition, 4b (2-F), showed good activity against 
both C. albicans species (30.8 µM), but not in C. krusei and C. parapsilosis.  These results 
indicate that the pyran groups on the chalcone or flavanone skeleton is a good scaffold for 
antifungal activity and that this activity can be increased by fluoro, methoxy and nitro groups 
being substituted on the phenyl ring or by substituting the phenyl ring with a naphthalene 
group.  However, these compounds were not as active as the standard drug amphotericin-B 
(Amp-B), whose MIC was at least 1 order of magnitude lower against all the fungal species 
tested against. 
 











2 332.9 332.9 332.9 332.9 
3a 128.7 64.4 32.2 32.2 
4a 64.4 64.4 64.4 64.4 
3b 30.8 61.5 246.0 246.0 
4b 30.8 30.8 61.5 246.0 
3d 30.8 61.5 61.5 61.5 
4d 30.8 61.5 30.8 30.8 
3e 117.8 117.8 117.8 117.8 
4e - - - - 
3f 59.7 59.7 119.5 239.0 
4f 29.9 29.9 59.7 29.9 
3h - - - 229.1 
4h 57.3 57.3 114.6 28.6 
3k 53.5 53.5 107.0 107.0 
4k 214.0 214.0 214.0 427.9 
3l 57.7 57.7 28.8 115.3 
4l 28.8 57.7 57.7 57.7 
3m 57.0 57.0 28.5 28.5 
 4m 228.1 228.1 228.1 114.0 
Amp-B 1.3 1.3 5.4 1.3 





The antioxidant activity of most of the chalcones was comparable to that of the control, 
ascorbic acid.  The chalcones that showed the best activity were 3e (2,4-difluoro), 3h (2-F, 3-
OCH3), 3i (2-Cl) and 3l (3-NO2).  The flavanones 4i (2-Cl) and 4l (3-NO2) (Table 4-3) also 
showed good antioxidant activity.  This indicates that a halogen substituted at position 2 or a 
withdrawing group such as nitro substituted at position 3 imparts good antioxidant activity on 
the prenylated chalcones and flavanones. 
 
Table 4-3  Antioxidant activity of the synthesized compounds by the DPPH assay (IC50, µM) 
Compound IC50  Compound IC50 
2 322.16 4a 427.25 
3a 281.70 4b 349.86 
3b 418.97 4c 339.35 
3c 250.26 4d 340.29 
3d 273.24 4e 381.02 
3e 230.42 4f 291.27 
3f 330.51 4g 423.92 
3g 433.52 4h 258.41 
3h 233.21 4i 225.80 
3i 228.73 4j 464.55 
3j 292.93 4k 260.81 
3k 269.61 4l 234.68 
3l 220.30 4m 328.68 
3m 282.71 5 254.96 
Ascorbic 
acid 
220.02   
 
Conclusion 
In summary, these findings show that the presence of phenolic hydroxyl and lipophilic 
pyranochromene rings contribute to the antimicrobial activity of chalcones and flavanones.  
The chalcones showed better activity than the flavanones in the antibacterial assay and the 
opposite was shown in the antifungal assays.  These pyranochromene containing chalcones 
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and flavanones could be good lead compounds for antimicrobial agents.  The antioxidant 
assay also indicate that these compounds could be good antioxidant leads. 
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Chapter 5. Synthesis and evaluation of pyridine, furan and fluoro-




A series of novel pyridine, furan and fluorosubstituted pyranochromene chalcones with 
different substituents on the phenyl ring were synthesized and tested for their antibacterial 
activity.  The synthesized compounds displayed moderate to significant in vitro antibacterial 
activity with the highest inhibitory activity being shown by the 2-trifluoromethyl derivative 
(6) (MIC of 13.7-27.5 µM) against all Gram negative strains.  The X-ray structure of 6 is also 
reported here. 
 






Pyranochalcones are synthetic or naturally occurring heterocyclic molecules and the 
precursors to flavonoids, both synthetically and naturally.  They consist of two aromatic rings 
joined by a three-carbon α,β-unsaturated carbonyl system with the pyran rings attached to the 
aromatic ring derived from the acetophenone portion of the molecule.  These 
pyranochalcones have been associated with a wide variety of biological activities, including 
antibacterial [1-2] and anticancer [3-4] activity.  They have also been reported to be used for 
neurological problems and inflammation [5-6].  This wide range of biological properties has 
stimulated interest in the synthesis of naturally occurring pyranochalcones [7-10].  Some of 
the naturally occurring pyranochalcones were isolated from Lonchocarpus subglaucescens 
[11],  Lonchocarpus utilus and Lonchocarpus urucu [12], Tephrosia tunicate [13], Tephrosia 
deflexa [14], Glycosmis citrifolia [15] and Mallotus philippensis [16-17].  The simple 
structure of these chalcones and easy method of preparation makes this class of compounds a 
desirable target for drug scaffolds with the aim of having important therapeutic potential.   
The bioactivities of these compounds have prompted us to investigate and develop a 
convenient and efficient method for synthesizing molecules with a pyranochromene moiety.  
To establish more advanced structure activity relationships with chromanochalcones, the 
chroman ring A was fixed, and more diverse substituents (both electron-donating and 
electron-withdrawing groups) such as methoxy, trifluoromethyl and fluorine groups were 
introduced at different positions on ring B of the chalcones (Scheme 5-1).  Further to this, 
pyridine and furan groups were also incorporated into the chromanochalcone skeleton.  The 
initial aim was to explore the influence that the different substituents and different 
heterocyclic groups had on biological activity.  To the best of our knowledge this is the first 





Reagent grade chemicals used in this study were purchased from Sigma Aldrich through 
Capital Laboratories, South Africa.  Organic solvents were distilled prior to being used and 
dried according to standard drying procedures.  Melting points were measured using a Stuart 
Scientific Melting Point Apparatus SMP3.  IR spectra were recorded on a Perkin Elmer 
spectrum 100 FT-IR instrument with a universal ATR attachment.  All 1H and 13C NMR 
spectra were recorded on Bruker AVANCE III 400 or 600 MHz instruments in CDCl3 
referenced to the internal standard TMS at δ 7.24 and 77.0 for 1H and 13C NMR respectively.  
For the 19F NMR spectra, the chemical shift of trifluorotoluene (0.05% in CDCl3) was 
referenced at -62.73 relative to TMS.  Chemical shifts are reported in ppm and coupling 
constants (J) in Hz.  High-resolution mass data was obtained using a Bruker microTOF-Q II 
ESI instrument operating at ambient temperatures, with a sample concentration of 
approximately 1 ppm.  Thin layer chromatography (TLC) was performed using Merck 
Kieselgel 60 F254 plates.  Crude compounds were purified with column chromatography using 
silica gel (60–120 mesh).   
 
Synthesis of octandrenolone 
Octandrenolone (2), was synthesized according to our previous method [18].  Briefly, 2,4,6-
trihydroxyacetophenone (2.00 g, 0.0119 mol), 2,3-dimethylbutenal (4.00 g, 0.0476 mol) and 
pyridine (1.35 g) were stirred for 24 h at 110°C.  The reaction was monitored by TLC using 
EtOAc:hexane (5:95, Rf = 0.6).  Upon completion, hydrochloric acid (30 mL) was added to 
neutralize the reaction mixture, which was then extracted with ethyl acetate (4 × 40 mL).  The 
organic portions were combined, dried over MgSO4 and the solvent evaporated under 
reduced pressure.  The residue was purified by column chromatography on silica gel using 
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100% hexane as the eluent to afford the pyranochromene as a yellow crystalline solid (2.58 g, 
yield 72.8%) with a melting point of 89–90 °C;  
 
1-(5-Hydroxy-2,2,8,8-tetramethyl-2H,8H-pyrano[2,3-f]chromen-6-yl)ethanone (2) 
1H NMR (600 MHz, CDCl3): δ 13.99 (1H, s, OH), 6.65 (1H, d, J = 10.1 Hz, H-1'''), 6.58 (1H, 
d, J = 10.1 Hz, H-1''), 5.45 (1H, d, J = 10.1 Hz, H-2''), 5.43 (1H, d, J = 10.1 Hz, H-2'''), 2.65 
(3H, s, CH3), 1.49 (6H, s, H-4''/5''), 1.43 (6H, s, H-4'''/H-5'''); 
13C NMR (150 MHz, CDCl3): 
203.5 (C=O), 160.7 (C-2'), 156.9 (C-6'), 155.2 (C-4'), 125.5 (C-2''), 124.9 (C-2'''), 116.6 (C-
1''), 116.3 (C-1'''), 105.7 (C-1'), 102.5 (C-3'), 102.4 (C-5'), 78.4 (C-3''), 78.3 (C-3'''), 33.4 
(CH3), 28.5 (C-4''/5''), 28.2 (C-4'''/5''');  IR υmax cm
-1 (neat): 2972, 2932, 1638, 1592, 1466. 
 
General procedure for the synthesis of the pyranochromene chalcones 3-9 
Octandrenolone 2 (150 mg, 0.500 mmol) was dissolved in ethanol (10 mL) and water (2 mL), 
after which, potassium hydroxide (112 mg, 2.00 mmol) and substituted aldehydes (0.7 mmol) 
were added at room temperature.  The reaction mixture was stirred for 24-48 h at room 
temperature and monitored by TLC using EtOAc:hexane (10:90, Rf = 0.4).  On completion, 
the solvent was removed under reduced pressure.  The residue was dissolved in water (20 
mL), acidified with 2 M HCl (20 mL), extracted with ethyl acetate (3 × 30 mL), washed with 
water and dried over anhydrous MgSO4.  Removal of the solvent followed by flash column 
chromatography on silica gel gave the pure compound as brown solids. 
 
1-(5-Hydroxy-2,2,8,8-tetramethyl-2H,8H-pyrano[2,3-f]chromen-6-yl)-3-pyridin-2-yl-
propenone (3), brown solid, 70% yield; mp. 65-66 oC; Rf = 0.6 (EtOAc:Hexane, 10:90); IR 
υmax cm
-1: 2966, 2922, 2852, 1638, 1583;  1H NMR (600 MHz, CDCl3): δ 14.18 (1H, s, OH), 
8.66 (1H, d, J = 4.1 Hz, H-2), 8.67 (1H, d, J = 15.4 Hz, H-8), 7.70 (1H, td, J = 8.1, 1.6 Hz, H-
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4), 7.64 (1H, d, J = 15.4 Hz, H-7), 7.44 (1H, d, J = 7.9 Hz, H-5), 7.22-7.24 (1H, m, H-3), 
6.68 (1H, d, J = 10.0 Hz, H-1'''), 6.59 (1H, d, J = 10.2 Hz, H-1''), 5.48 (1H, d, J = 10.2 Hz, H-
2''), 5.47 (1H, d, J = 10.0 Hz, H-2'''), 1.56 (6H, s, H4''/5''), 1.45 (6H, s, H-4'''/5'''); 13C NMR 
(150 MHz, CDCl3): 193.6 (C-9), 161.5 (C-2'), 156.7 (C-6'), 155.7 (C-4'), 154.3 (C-6), 150.4 
(C-2), 140.0 (C-7), 136.7 (C-4), 132.3 (C-8), 125.6 (C-2''), 125.3 (C-2'''), 124.5 (C-5), 123.9 
(C-3), 116.5 (C-1''), 116.4 (C-1'''), 106.3 (C-1'), 102.8 (C-3'), 102.7 (C-5'), 78.7 (C-3''), 78.6 




propenone (4), brown solid; 67% yield; mp. 77-78 oC; Rf = 0.6 (EtOAc:Hexane, 10:80); IR 
υmax cm
-1 (neat): 2972, 2923, 2853, 1631, 1583, 1534;   1H NMR (600 MHz, CDCl3): δ 14.43 
(1H, s, OH), 8.04 (1H, d, J = 15.4 Hz, H-7), 7.54 (1H, d, J = 15.4 Hz, H-6), 7.51 (1H, s, H-2), 
6.68 (1H, d, J = 10.0 Hz, H-1'''), 6.66 (1H, d, J = 3.3 Hz, H-4), 6.59 (1H, d, J = 9.8 Hz, H-1''), 
6.49-6.50 (1H, m, H-3), 5.47 (1H, d, J = 9.8 Hz, H-2''), 5.47 (1H, d, J = 10.0 Hz, H-2'''), 1.56 
(6H, s, H4''/5''), 1.45 (6H, s, H-4'''/5'''); 13C NMR (150 MHz, CDCl3): 192.6 (C8), 161.7 (C-
2'), 156.4 (C-6'), 155.5 (C-4'), 152.6 (C-5), 144.9 (C-2), 128.8 (C-6), 125.5 (C-7), 125.1 (C-
2''/2'''), 116.6 (C-1''), 116.4 (C-1'''), 115.4 (C-4), 112.7 (C-3), 106.1 (C-1'), 102.76 (C-3'), 
102.75 (C-5'), 78.6 (C-3''), 78.5 (C-3'''), 28.6 (C-4'''/5'''), 28.0 (C-4''/5''); HRMS m/z 377.1389 
(Calcd. for C23H21O5, 377.1389). 
 
1-(5-Hydroxy-2,2,8,8-tetramethyl-2H,8H-pyrano[2,3-f]chromen-6-yl)-3-(2,4,6-
trimethoxyphenyl)-propenone (5), brown solid; 72% yield; mp. 89-90 oC; Rf = 0.6 
(EtOAc:Hexane, 10:90); IR υmax cm
-1: 2928, 1637, 1603, 1583, 1523;  1H NMR (600 MHz, 
CDCl3): δ 14.74 (1H, s, OH), 8.26
* (1H, d, J = 15.8 Hz, H-8), 8.23* (1H, d, J = 15.8 Hz, H-
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7), 6.69 (1H, d, J = 9.9 Hz, H-1'''), 6.60 (1H, d, J = 9.8 Hz, H-1''), 6.14 (2H, s, H-3/5), 5.45 
(1H, d, J = 9.8 Hz, H-2''), 5.44 (1H, d, J = 9.9 Hz, H-2'''), 3.88 (6H, s, H-10/12), 3.85 (3H, s, 
H-11), 1.50 (6H, s, H-4''/5''), 1.44 (6H, s, H-4'''/5'''); 13C NMR (150 MHz, CDCl3): 194.8 (C-
9), 163.0 (C-4), 161.8 (C-2/6), 161.6 (C-2'), 156.3 (C-6'), 154.7 (C-4'), 134.1 (C-7), 127.7 (C-
8), 125.3 (C-2''), 125.0 (C-2'''), 116.8 (C-1''), 116.7 (C-1'''), 107.4 (C-1), 106.5 (C-1'), 102.7 
(C-3'), 102.5 (C-5'), 90.8 (C-3/5), 78.1 (C-3''), 78.0 (C-3'''), 56.1 (C10/12), 55.6 (C-11), 28.5 
(C-4'''/5'''), 27.8 (C-4''/5'');  HRMS m/z 477.1922 (calcd. for C28H29O7, 477.1913). 
* resonances coalesce 
 
 1-(5-Hydroxy-2,2,8,8-tetramethyl-2H,8H-pyrano[2,3-f]chromen-6-yl)-3-(2-
trifluoromethylphenyl)-propenone (6), brown solid; 90% yield; mp. 112-113 oC; Rf = 0.6 
(EtOAc:Hexane, 10:90); IR υmax cm
-1: 2975, 2928, 1634, 1586, 1549; 1H NMR (400 MHz, 
CDCl3): δ 14.16 (1H, s, OH), 8.08 (1H, dq, J = 15.4, 2.0 Hz, H-7), 8.01 (1H, d, J = 15.4 Hz, 
H-8), 7.79 (1H, d, J = 7.8 Hz, H-6), 7.72 (1H, d, J = 7.8 Hz, H-3), 7.59 (1H, t, J = 7. 6 Hz, 
H4), 7.47 (1H, t, J = 7.6 Hz, H-5), 6.69 (1H, d, J = 10.0 Hz, H-1'''), 6.60 (1H, d, J = 9.9 Hz, 
H-1''), 5.48 (1H, d, J = 9.9 Hz, H-2''), 5.46 (1H, d, J = 10.0 Hz, H-2'''), 1.50 (6H, s, H-4''/5''), 
1.45 (6H, s, H-4'''/5'''); 13C NMR (100 MHz, CDCl3): 192.5 (C-9), 161.6 (C-2'), 156.4 (C-6'), 
155.8 (C-4'), 136.9 (q, J = 2.0 Hz, C-7), 134.9 (q, J = 1.3 Hz, C-2), 132.1 (C-4), 131.9 (C-8), 
129.4 (C-5), 127.7 (C-6), 126.5 (q, J = 5.7 Hz, C-3), 125.6 (C-2''), 125.0 (C-2'''), 122.9 (C-1), 
116.8 (C-1''), 116.4 (C-1'''), 106.1 (C-1'), 102.9 (C-3'), 102.8 (C-5'), 78.6 (C-3''), 78.6 (C-3'''), 
28.6 (C-4''/5''), 28.3 (C-4'''/5''');  19F NMR (CDCl3, 376.5 MHz) δ -58.84;  HRMS m/z 
455.1470 (calcd. for C26H22O4F3, 455.1470). 
 
1-(5-Hydroxy-2,2,8,8-tetramethyl-2H,8H-pyrano[2,3-f]chromen-6-yl)-3-(3-
trifluoromethylphenyl)-propenone (7), brown solid; 87% yield; mp. 74-75 oC;  Rf = 0.6 
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(EtOAc:Hexane, 10:90); IR υmax cm
-1: 2977, 2930, 1632, 1582, 1539; 1454;  1H NMR (400
MHz, CDCl3): δ 14.23 (1H, s, OH), 8.16 (1H, d, J = 15.7 Hz, H-8), 7.90 (1H, s, H-2), 7.73 
(1H, d, J = 15.7 Hz, H-7), 7.71 (1H, d, J = 7.8 Hz, H-6), 7.62 (1H, d, J = 7.8 Hz, H-4), 7.54 
(1H, t, J = 7.6 Hz, H-5), 6.69 (1H, d, J = 10.0 Hz, H-1'''), 6.61 (1H, d, J = 9.9 Hz, H-1''), 5.48 
(2H, d, J = 10.0 Hz, H-2''/2'''), 1.55 (6H, s, H-4''/5''), 1.46 (6H, s, H-4'''/5'''); 13C NMR (100 
MHz, CDCl3): 192.6 (C-9), 161.7 (C-2'), 156.5 (C-6'), 155.8 (C-4'), 140.0 (C-7), 136.7 (C-1), 
132.0 (C-6), 131.6 (q, J = 32.3, C-3), 129.8 (C-5), 129.7 (C-8), 126.4 (q, J = 3.7 Hz, C-4), 
125.7 (C-2''), 125.1 (C-2'''), 124.2 (q, J = 3.8, C-2), 116.8 (C-1''), 116.3 (C-1'''), 106.0 (C-1'), 
102.9 (C-3'), 102.8 (C-5'), 78.7 (C-3''), 78.5 (C-3'''), 28.7 (C-4''/5''), 28.2 (C-4'''/5'''); 19F NMR 
(CDCl3, 376.5 MHz) δ -63.01;  HRMS m/z 455.1470 (Calcd. for C26H22O4F3, 455.1470). 
 
1-(5-Hydroxy-2,2,8,8-tetramethyl-2H,8H-pyrano[2,3-f]chromen-6-yl)-3-(4-
trifluoromethylphenyl)-propenone (8), brown solid, 91% yield; mp. 125-126 oC;  Rf = 0.6 
(EtOAc:Hexane, 10:90); IR υmax cm
-1: 2979, 2934, 1629, 1581, 1545;  1H NMR (400 MHz, 
CDCl3): δ 14.18 (1H, s, OH), 8.12 (1H, d, J = 15.6 Hz, H-8), 7.72 (1H, d, J = 15.6 Hz, H-7), 
7.67 (4H, br s, H-2/3/5/6), 6.68 (1H, d, J = 10.0 Hz, H-1'''), 6.61 (1H, d, J = 9.9 Hz, H-1''), 
5.49 (1H, d, J = 9.9 Hz, H-2''), 5.47 (1H, d, J = 9.9 Hz, H-2'''), 1.54 (6H, s, H-4''/5''), 1.46 
(6H, s, H-4'''/5'''); 13C NMR (100 MHz, CDCl3): 192.7 (C-9), 161.6 (C-2'), 156.4 (C-6'), 
155.9 (C-4'), 139.9 (C-7), 139.3 (C-1), 131.5 (q, J = 32.5 Hz, C-4), 130.3 (C-8), 128.4 (C-
2/6), 126.1 (q, J = 3.8 Hz, C-3/5), 125.7 (C-2''), 125.0 (C-2'''), 116.8 (C-1''), 116.3 (C-1'''), 
106.1 (C-1'), 102.9 (C-3'), 102.8 (C-5'), 78.7 (C-3''), 78.6 (C-3'''), 28.7 (C-4''/5''), 28.3 (C-






propenone (9), brown solid, 90% yield, mp. 149-150 oC; Rf = 0.6 (EtOAc:Hexane, 10:90); IR 
υmax cm
-1: 2972, 2929, 1633, 1587, 1510; 1H NMR (400 MHz, CDCl3): δ 14.00 (1H, s, OH), 
7.98 (1H, d, J = 15.6 Hz, H-8), 7.62 (1H, d, J = 15.6 Hz, H-7), 7.39 (1H, ddd, J = 10.0, 7.6, 
1.8, H-2), 7.29-7.32 (1H, m, H-6), 7.19 (1H, dd, J = 17.9, 8.3 Hz, H-5), 6.68 (1H, d, J = 10.0 
Hz, H-1'''), 6.61 (1H, d, J = 9.9 Hz, H-1''), 5.49 (2H, d, 9.9 Hz, H-2''/2'''), 1.54 (6H, s, H-
4''/5''), 1.46 (6H, s, H-4'''/5'''); 13C NMR (100 MHz, CDCl3): 192.6 (C-9), 161.6 (C-2'), 156.4 
(C-6'), 155.8 (C-4'), 151.5 (dd, J = 251.5, 12.9 Hz, C-3), 150.8 (dd, J = 247.7, 12.9 Hz, C-4), 
139.6 (C-7), 133.2 (dd,  J = 5.6, 4.4 Hz, C-1), 128.8 (d, J = 2.3 Hz, C-8), 125.7 (C-2''), 125.1 
(dd, J = 6.5, 3.5 Hz, C-6), 124.9 (C-2'''), 118.1 (d, J = 17.5 Hz, C-5), 116.8 (C-1''), 116.34 (C-
1'''), 116.33 (d, J = 17.5 Hz, C-2), 106.1 (C-1'), 102.9 (C-3'), 102.8 (C-5'), 78.7 (C-3''), 78.6 
(C-3'''), 28.6 (C-4'''/5'''), 28.3 (C-4''/5''); 19F NMR (CDCl3, 376.5 MHz) δ -134.63 (d, J = 20.9 
Hz), -136.68 (d, J = 20.9 Hz);  HRMS m/z 423.1409 (Calcd. for C25H21O4F2, 423.1408). 
 
Single crystal X-Ray diffraction analysis 
Cube-shaped single crystals of compound 6 was selected and glued onto a glass fibre tip, 
mounted in a stream of cold nitrogen at 173(1) K and centred in the X-ray beam using a video 
camera.  Crystal evaluation and data collection were performed on a Bruker Smart APEXII 
diffractometer with Mo Kα radiation (λ = 0.71073 Å).  The diffractometer to crystal distance 
was set at 4.00 cm.  The initial cell matrix was obtained from three series of scans at different 
starting angles.  Each series consisted of 12 frames collected at intervals of 0.5º in a 6º range 
with the exposure time of 10 seconds per frame.  The reflections were successfully indexed 
by an automated indexing routine built in the APEXII program suite.  The final cell constants 
were calculated from a set of 6460 strong reflections from the actual data collection.  Data 
collection method involved ω scans of width 0.5°.  Data reduction was carried out using the 
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program SAINT+.  The structure was solved by direct methods using SHELXS and refined.  
Non-H atoms were first refined isotropically and then by anisotropic refinement with full-
matrix least-squares calculations based on F2 using SHELXS.  All H atoms were positioned 
geometrically and allowed to ride on their respective parent atoms.  All H atoms were refined 
isotropically.  The absorption correction was based on fitting a function to the empirical 
transmission surface as sampled by multiple equivalent measurements.  The program 
ORTEP3 was used to prepare artwork representation.  The molecular diagrams are drawn 
with 50% probability ellipsoids.  Crystallographic data (excluding structure factors) for the 
structure in this paper has been deposited with the Cambridge Crystallographic Data Centre, 
CCDC, 12 Union Road, Cambridge CB21EZ, UK.  Copies of the data can be obtained free of 
charge on quoting the depository numbers CCDC- 1047148 (Fax: +44-1223-336-033; E-
Mail: deposit@ccdc.cam.ac.uk, http://www.ccdc.cam.ac.uk). 
 
Antimicrobial activity 
Antimicrobial agents:  Stock solutions of 2mM of the test compounds were prepared in 
DMSO and diluted before assays.  Neomycin purchased from Sigma Aldrich was used as a 
reference drug for the antibacterial assays and amphotericin-B was used as a reference for the 
antifungal assays.  The final concentration of antimicrobial agents ranged from 2.5 nM to 
530.3 µM, neomycin was between 12.3 nM to 813.5 µM and amphotericin-B from 8.2 nM to 
541.4 µM.  All drug dilutions were carried out in 96-well flat bottom microtitre plates.  The 
final concentration of DMSO in each well was 2 nM or 0.001%. 
Antimicrobial susceptibility tests:  Microbial susceptibility tests were carried out using the 
micro broth dilution method.  Overnight cultures (after 16-18 h of incubation at 37 ºC) were 
adjusted to the turbidity of a 0.5 McFarland standard.  Inocula were adjusted to 0.08 - 0.1 to 
yield a stock suspension of 0.4-5×108 CFU mL-1, which was diluted one hundred fold to 
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obtain a working suspension of 106 CFU mL-1 at 625 nm.  Microtitre plates were placed in a 
laminar flow unit to equilibrate to room temperature under aseptic conditions.  Aliquots of 
100 µL of bacterial/fungal inoculate were added to the microtiter plates containing different 
concentrations of test compounds.  Plates were incubated aerobically for 16-18 h at 37 °C.  
Following incubation, 40 µL of freshly prepared iodonitrotetrazolium chloride [2-(4-
iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H tetrazolium chloride] (INT) solution (200 µg mL-
1) was added to each well and the plate further incubated for 45 minutes at 37 ºC in the dark.  
Persistent growth of bacteria/fungi is indicated if the colourless INT is reduced to red after 
incubation.  No color change denotes the lack of bacterial growth.  All analyses were 
performed in triplicate. 
 
Results and Discussion 
Chemistry 
A series of pyranochromene chalcones 3-9 (Scheme 5-1) were synthesized in quantitative 
yields from commercially available 2,4,6-trihydroxy acetophenone (1) in two steps, forming 
the pyranochromene acetophenone, octandrenolone (2) in the first step with 3-methyl-2-
butenal [18], followed by a Claisen-Schmidt condensation with various benzaldehydes, 




Scheme 5-1  Synthetic route to the pyranochromene chalcones.  Reagents:  i) 3-methy 2-
butenal, pyridine, 110°C, reflux; ii) substituted benzaldehydes, KOH, EtOH/H2O, rt.  
 
The compounds were characterized by 1D and 2D NMR spectroscopy.  In the 1H NMR 
spectrum of 3 (pyridine derivative), the trans α,β-unsaturated double bond occurred at the 
typical resonances of δ 7.64 (H-7) and δ 8.67 (H-8) with J = 15.4 Hz.  The hydroxyl proton 
occurred as a singlet at δ 14.18.  The pyran rings were indicated by the olefinic resonances at 
δ 6.68 and δ 5.47 (H-1''' and H-2''' respectively) with J = 10.0 Hz and δ 6.59 and δ 5.48 (H-1'' 
and H-2'' respectively) with J = 10.2 Hz.  In addition, the equivalent methyl groups of the 
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pyran rings could be seen as singlets at δ 1.56 (H-4''/H-5'') and δ 1.45 (H-4'''/5''').  The 
pyridine proton resonances occurred as doublets at δ 8.66 (J = 4.1 Hz, H-2) and δ 7.44 (J = 
7.9 Hz, H-5), a triplet of doublets at δ 7.70 (J = 8.1, 1.6 Hz, H-4) and a multiplet at δ 7.22-
7.24 (H-3).  For the furan derivative 4, the furan protons were present at δ 7.51 (s, H-2), δ 
6.66 (d, J = 3.3 Hz, H-4) and δ 6.49-6.50 (m, H-3).   
For the 2,4,6-trimethoxy derivative 5, a singlet was seen for the equivalent H-3 and H-5 
protons at δ 6.14.  For the 2-trifluoromethylphenyl (2-CF3) derivative 6, H-3 and H-6 
occurred as doublets at δ 7.72 and δ 7.79 respectively with J = 7.8 Hz each and H-4 and H-5 
appeared as triplets at δ 7.59 and δ 7.47 respectively with J = 7.6 Hz each.  In compound 7, 
the 3-CF3 derivative, H-2 occurs as a singlet at δ 7.90, both H-4 and H-6 occur as doublets at 
δ 7.62 and 7.71 with J = 7.8 Hz each and H-5 is present as a triplet at δ 7.54 (J = 7.6 Hz).  In 
the 4-CF3 derivative 8, the equivalent H-2/6 and H-3/5 resonances co-incided and appeared as 
a broad singlet at δ 7.67.  For the difluorinated phenyl ring in compound 9, H-F coupling was 
also evident, which resulted in H-2 being present as a ddd at δ 7.39 with J = 10.0, 7.6 and 1.8 
Hz, H-5 occurring as a dd at δ 7.19 (J = 17.9 and 8.3 Hz) and H-6 occurring as a multiplet at 
δ 7.29-7.32.  C-F coupling was also evident in the 13C NMR spectrum with the two carbon 
resonances where the F was present occurring as a dd at δ 151.5 (J = 251.5, 12.9 Hz, C-3) 
and δ 150.8 (J = 247.7, 12.9 Hz, C-4), the carbon atoms ortho to the F occurring as doublets 
at δ 116.3 (J = 17.5 Hz, C-2) and δ 118.1 (J = 17.5 Hz, C-5) and C-6 being present as a dd at 
δ 125.1 (J = 6.5, 3.5 Hz). 
Crystal structure 
The crystal structure of 6 showed the planarity of these molecules with the methyl groups of 
the pyran rings going into and out of the plane respectively.  The trans double bond was also 
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indicated by the torsion angle of C17-C18-C19-C20, which was found to be -177.20º (9) in 
the crystal.  The crystal structure was solved in the monoclinic space group P21/c, with one 
molecule in the asymmetric unit (Table 5-1).  The bond length and angles are in agreement 
with the expected average values for related compounds [18-19].  The carbonyl group is in a 
cis configuration with respect to the olefinic double bond.  The crystal structure is stabilized 
by C=O—O-H intramolecular hydrogen bonding (Figure 5-1).  Both pyranochromene rings 
exist in a half chair conformation with Q = 0.3400(10) Å, θ = 113.84(18)°, Ψ = 218.20 (19)° 
and Q = 0.3382(10) Å, θ = 64.76 (17)° and Ψ = 33.2(2)° respectively.  This is similar to our 
previous reported structures, which also resemble this conformation [18].  The dihedral angle 
between the least-squares plane of the pyranochromene ring system and its nearest phenyl 
ring is 15.04 (10)°. 
 
 
Figure 5-1  Crystal structure of 1-(5-hydroxy-2,2,8,8-tetramethyl-2H,8H-pyrano[2,3-




Table 5-1  Crystal data and structure refinement for 1-(5-hydroxy-2,2,8,8-tetramethyl-
2H,8H-pyrano[2,3-f]chromen-6-yl)-3-(2-trifluoromethyl-phenyl)-propenone (6) 
Empirical formula  C26 H23 F3 O4 
Formula weight  456.44 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 9.5858(5) Å ; α = 
81.443(3)° 
 b = 10.0120(5) Å ; β = 
80.132(3)° 
 c = 12.0479(7) Å ; γ = 
74.075(2)° 
Volume 1089.11(10) Å3 
Z 2 
Density (calculated) 1.392 Mg/m3 
Absorption coefficient 0.110 mm-1 
F(000) 476 
Crystal size 0.32 x 0.17 x 0.16 mm3 
Theta range for data collection 1.73 to 28.31° 
Reflections collected 28617 
Independent reflections 5420 [R(int) = 0.0195] 
Completeness to theta = 28.31° 99.7 %  
Goodness-of-fit on F2 1.048 
Final R indices [I>2sigma(I)] R1 = 0.0354, wR2 = 0.0980
R indices (all data) R1 = 0.0409, wR2 = 0.1026
 
Antimicrobial activity 
All synthesized compounds were evaluated for their antimicrobial activity on a panel of five 
bacterial strains and four fungal strains.  For each compound, the minimum inhibitory 
concentration (MIC) was calculated (Table 5-2). 
Most of the compounds showed good activity against the Gram negative strains i.e. 
Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa (MICs between 13.7 
– 132.6 µM) in comparison to neomycin (16.3 µM).  All synthesized compounds did not 
exhibit any activity against the Gram positive strains (S. aureus and E. faecalis).  The best 
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activity was shown by compound 6 (2-CF3 derivative), with MICs of 13.7 µM for E. coli and 
K. pneumonia and 27.5 µM for P. aeruginosa.  The activity against E. coli and K. pneumonia 
was similar to the control, neomycin, which had a MIC of 16.3 µM in the same assay.  The 
other compounds showed activity in the order of 7 (3-CF3 derivative) > 9 (difluoro 
derivative) > 3 (pyridine derivative) > 5 (trimethoxy derivative) > 4 (furan derivative).  
Surprisingly, compound 8 (4-CF3 derivative) showed no activity against these Gram negative 
strains.  In general, the fluorinated derivatives showed better activity than the heterocyclic 
and trimethoxyphenyl derivatives. 
 
Table 5-2  Antimicrobial activity of pyranochromene chalcones 3-9 (MIC, µΜ) 




























3 32.2 32.2 32.2 257.6 257.6 128.8 128.8 
4 66.3 132.6 132.6 - - - 530.3 
5 52.4 52.4 52.4 104.8 104.8 209.6 26.2 
6 13.7 13.7 27.5 - - - - 
7 27.5 27.5 27.5 - - - - 
8 - - - 27.5 27.5 54.9 54.9 
9 29.5 29.5 29.5 - - 472.7 - 
Control 16.3 16.3 16.3 6.8 6.8 3.4 3.4 
“-’’ indicates no activity. Data reported as the mean ±standard error of the mean ≤5; * Neomycin served as the 
control for the antibacterial assay and Amphotericin-B as the control for the antifungal assay; All compounds 
had no activity against S. aureus (ATCC 43300) and E. faecalis (ATCC 5129) 
 
Four strains of Candida were employed in evaluating the antifungal potency of the 
compounds.  Here, only compound 8 (the inactive antibacterial compound), showed 
appreciable activity against the antifungal strains tested with MICs of between 27.5-54.9 µM 
(Table 5-2).  This was 1 to 2 orders of magnitude higher than amphotericin-B, the control, 
which had MICs ranging from 3.4 – 6.8 µM.  All the other compounds showed either high or 
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no activity.  The only exception was compound 5 (trimethoxy derivative), which showed a 
MIC of 26.2 µM for C. parapsilosis only.   
 
Conclusions 
Seven novel pryanochalcones bearing pyridine, furan, trimethoxyphenyl, 
trifluoromethylphenyl and difluorophenyl moieties were synthesized in good yields.  
Compound 6 (2-CF3 derivative) showed excellent antibacterial activity against E. coli, K. 
pneumoniae and P. aeruginosa, comparable to neomycin, with the compounds 7 (3-CF3 
derivative), 9 (difluoro derivative) and 3 (pyridine derivative) also showing comparable 
activity to neomycin.  Only compound 8 (4-CF3 derivative) showed appreciable activity 
against the fungal species used in this assay.   The data indicates that the CF3 moiety is a 
good substituent for antimicrobial activity, better than other heterocyclic rings and the fluoro 
substituent.  The best position for this group with regard to antibacterial activity is C-2 on the 
B ring of the chalcone and C-4 with regard to antifungal activity. 
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Chapter 6. Synthesis, characterization, antimicrobial and antioxidant 
study of pyranopyrazoline derivatives 
 
Abstract 
Novel halogenated pyranochromene pyrazolines 4a – 4k and N-pyrazolines 5a - 5k were 
synthesized.  The compounds were screened for in vitro antimicrobial and antioxidant 
activity.  Compounds 4e and 4i showed significant antibacterial activity against a –ve strain 
of bacteria (Pseudomonas aeruginosa).  Some of these derivatives also exhibited moderate 
antifungal activity.  These compounds showed moderate to potent antioxidant properties in 
comparison to ascorbic acid.  
 





The overuse of antibiotics has led to microbes becoming resistant to them and some strains 
are resistant to almost all available antibiotics [1].  In a recent World Health Organisation 
Report on antimicrobial resistance [2], strains of E. Coli and K. pneumonia were reportedly 
resistant to cephalosporins in many regions and in some regions, resistance to carbapenems 
were also reported.  These are antibiotics used as a last resort to these infections.  In addition, 
second line drugs are now being used for MRSA infections as first line drugs are no longer 
effective [2].  These second line drugs are more expensive and have more side effects.  
Streptococcus pneumonia was also reported to be resistant to penicillin in all WHO areas and 
diarrhea causing non-typhoidal Salmonella and Shigella species were reported in some 
instances to be resistant to the fluoroquinolones [2].  There is thus an urgent need to find new 
and safe antibiotics, which can be used in the fight against antimicrobial resistance. 
Pyrazolines can easily be prepared from the reaction of hydrazine or hydrazine derivatives 
with chalcone precursors, reacting at the α,β-unsaturated ketone moiety of the molecule.  In 
the last ten years, pyrazolines and their N-substituted analogues prepared in this manner have 
shown promising antimicrobial activity [3-10].  There has been a recent interest in the 
antibacterial activity of these compounds with numerous reports on the synthesis and 
antibacterial activity of pyrazolines [11-20].  In addition they have also displayed several 
other medicinal applications such as antiamoebics [21], monoamine oxidase (MAO) 
inhibitors [22-23], antioxidants [10, 24-26], anti-inflammatory [25-27] and anticancer agents 
[26, 28-30].  In search of more potent antibiotics, we herein report an efficient and simple 
methodology for the synthesis of halogenated pyranopyrazolines from 2,4,6-trihydroxy 
acetophenone.  The synthesized compounds were screened for their in vitro antibacterial, 





Reagent grade chemicals used in this study were purchased from Sigma Aldrich through 
Capital Laboratories, South Africa.  Organic solvents were distilled prior to being used and 
dried according to standard drying procedures.  Melting points were measured using a Stuart 
Scientific Melting Point Apparatus SMP3.  IR spectra were recorded on a Perkin Elmer 
spectrum 100 FT-IR instrument with a universal ATR attachment.  All 1H and 13C NMR 
spectra were recorded on Bruker AVANCE III 400 or 600 MHz instruments in CDCl3 
referenced to the internal standard TMS at δ 7.24 and 77.0 for 1H and 13C NMR respectively.  
For the 19F NMR spectra, the chemical shift of trifluorotoluene (0.05% in CDCl3) was 
referenced at -62.73 relative to TMS.  Chemical shifts are reported in ppm and coupling 
constants (J) in Hz.  High-resolution mass data was obtained using a Bruker microTOF-Q II 
ESI instrument operating at ambient temperatures, with a sample concentration of 
approximately 1 ppm.  Thin layer chromatography (TLC) was performed using Merck 
Kieselgel 60 F254 plates.  Crude compounds were purified with column chromatography using 
silica gel (60–120 mesh).   
 
Synthesis of 1-(5-hydroxy-2,2,8,8-tetramethyl-2H,8H-pyrano[2,3-f]chromen-6-yl) 
ethanone (2) 
For the synthesis of octandrenolone (1-(5-hydroxy-2,2,8,8-tetramethyl-2H,8H-pyrano[2,3-
f]chromen-6-yl)ethanone) (2), the method in Pawar et al. [31] was followed and the NMR 
data compared with those of an authentic sample prepared earlier. 
 
General procedure for the synthesis of pyranochromene-chalcones (3a-k) 
The chalcones 3a-k were prepared according to our previously described methods in chapters 
4 and 5 (Scheme 6-1).  Briefly, substituted benzaldehydes (0.6 mmol) were added at room 
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temperature along with KOH (112 mg, 2 mmol) to a solution of octandrenolone (2) (150 mg, 
0.5 mmol) in ethanol (10 mL) and water (2 mL).  The reaction mixture was stirred for 24 – 48 
h at room temperature and monitored by TLC using EtOAc:hexane (10:90, Rf = 0.4).  
Thereafter, the solvent was evaporated, dissolved in water (20 mL), neutralised with 2 M HCl 
(20 mL) and extracted with ethyl acetate (3 × 30 mL), washed with water and dried over 
anhydrous MgSO4.  Removal of the solvent followed by flash column chromatography on 
silica gel gave the pure compounds 3a – 3k as brown solids.  These compounds are fully 
characterized in chapters 4 and 5. 
Synthesis of pyranochromene-pyrazolines (4a – 4k) 
Hydrazine hydrate (80 µL, 1.44 mmol) was added under a nitrogen atmosphere to a solution 
of substituted chalcone (0.5 mmol) in ethanol (7 mL).  The reaction mixture was heated under 
reflux at 80 oC for 2-4 h and the progress monitored by TLC using EtOAc:hexane (10:90, Rf 
= 0.4).  After completion, the resulting solution was cooled and poured onto crushed ice.  The 
solution was filtered and recrystallized from EtOH to yield the solid pyrazolines (4a-k), each 
with Rf values of approximately 0.6 in EtOAc:Hexane (10:90).  The 1H and 13C NMR data of 
4a-k are reported in Table 6-1 and Table 6-2. 
6-(5-(2-Chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl)-2,2,8,8-tetramethyl-2,8-
dihydropyrano[2,3-f]chromen-5-ol (4a) yellow solid; Yield 69%; mp 78-79 oC; IR υmax 2973, 
2926, 1638, 1593, 1437, 1361 cm-1; HRMS m/z 435.1465 [M-H]+ (calcd. for C25H24N2O3Cl 
435.1475).   
 
6-(5-(4-Chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl)-2,2,8,8-tetramethyl-2,8-
dihydropyrano[2,3-f]chromen-5-ol (4b) white solid; Yield 78%; mp 113-114 oC; IR υmax 






dihydropyrano[2,3-f]chromen-5-ol (4c) yellow solid; Yield 73%; mp 96-97 o C; IR υmax  




dihydropyrano[2,3-f]chromen-5-ol (4d) yellow solid; Yield 76%; mp 79-80 oC; 19F NMR 
(376 MHz, CDCl3) δ -114.60; IR υmax 2974, 2926, 1637, 1591, 1455, 1361 cm
-1; HRMS m/z 
419.1783 [M-H]+ (calcd. for C25H24N2O3F 419.1771).  
 
6-(5-(3-Fluorophenyl)-4,5-dihydro-1H-pyrazol-3-yl)-2,2,8,8-tetramethyl-2,8-
dihydropyrano[2,3-f]chromen-5-ol (4e) yellow solid; Yield 69%; mp 89-90 oC; 19F NMR 
(376 MHz, CDCl3) δ -112.26; IR υmax 3319, 3282, 2973, 2926, 1634, 1590, 1433, 1356 cm
-1; 
HRMS m/z 419.1776 [M-H]+ (calcd. for C25H24N2O3F 419.1771). 
 
6-(5-(4-Fluorophenyl)-4,5-dihydro-1H-pyrazol-3-yl)-2,2,8,8-tetramethyl-2,8-
dihydropyrano[2,3-f]chromen-5-ol (4f) brown solid; Yield 70%; mp 91-92 oC; 19F NMR (376 
MHz, CDCl3) δ -114.61; IR υmax 3290, 2971, 2923, 1633, 1592, 1509, 1358 cm
-1; HRMS m/z 
419.1783 [M-H]+ (calcd. for C25H24N2O3F 419.1771). 
 
6-(5-(2,4-Difluorophenyl)-4,5-dihydro-1H-pyrazol-3-yl)-2,2,8,8-tetramethyl-2,8-
dihydropyrano[2,3-f]chromen-5-ol (4g) yellow solid; Yield 80%; mp 55-56 oC; 19F NMR 
(376 MHz, CDCl3) δ -111.16 (d, J = 7.3 Hz), -114.70 (d, J = 7.3 Hz); IR υmax 2973, 2930, 






dihydropyrano[2,3-f]chromen-5-ol (4h) brown solid; Yield 65%; mp 82-83 oC; 19F NMR 
(376 MHz, CDCl3) δ -136.75 (d, J = 21.2 Hz), -139.12 (d, J = 21.2 Hz); IR υmax 3327, 2978, 




dihydropyrano[2,3-f]chromen-5-ol (4i) yellow solid; Yield 97%; mp 69-70 oC; 19F NMR 
(376 MHz, CDCl3) δ -58.63; IR υmax 3333, 2975, 2932, 1640, 1593, 1455, 1431, 1362, 1311 
cm-1; HRMS m/z 469.1747 [M-H]+ (calcd. for C26H24N2O3F3 469.1739). 
 
2,2,8,8-Tetramethyl-6-(5-(3-(trifluoromethyl)phenyl)-4,5-dihydro-1H-pyrazol-3-yl)-2,8-
dihydropyrano[2,3-f]chromen-5-ol (4j) yellow solid; Yield 55%; mp 51-52 oC; 19F NMR 
(376 MHz, CDCl3) δ -62.58; IR υmax 2975, 2928, 1639, 1593, 1325 cm
-1; HRMS m/z 
469.1747 [M-H]+ (calcd. for C26H24N2O3F3 469.1739). 
 
2,2,8,8-Tetramethyl-6-(5-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-pyrazol-3-yl)-2,8-
dihydropyrano[2,3-f]chromen-5-ol (4k) white solid; Yield 77%; mp 124-125 oC; 19F NMR 
(376 MHz, CDCl3) δ -62.56; IR υmax 3299, 3237, 2981, 2922, 1643, 1614, 1591, 1328 cm
-1; 
HRMS m/z 469.1752 [M-H]+ (calcd. for C26H24N2O3F3 469.1739). 
 
General procedure for the synthesis of pyranochromene-N-pyrazolines (5a – 5k) 
Phenyl hydrazine hydrate (56 µl, 0.52 mmol) was added under nitrogen atmosphere using a 
micropippette to a solution of substituted chalcone (0.5 mmol) in ethanol (7 mL).  The 
reaction mixture was heated under reflux at 80 oC for 2 – 4 h and the progress of the reaction 
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monitored by TLC using EtOAc:hexane (10:90, Rf = 0.4).  After completion of the reaction, 
the resulting solution was cooled and poured onto crushed ice.  The solid pyrazoline was 
filtered and recrystallized from EtOH to produce the pyranochromene-N-pyrazolines (5a-k).  
For the 1H and 13C NMR data, see Table 6-3 and Table 6-4. 
6-(5-(2-Chlorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-2,2,8,8-tetramethyl-2,8-
dihydropyrano[2,3-f]chromen-5-ol (5a) brown solid; Yield 71%; mp 92-93 oC; IR υmax 2975, 




dihydropyrano[2,3-f]chromen-5-ol (5b) yellow solid; Yield 79%; mp 177-178 oC; IR υmax 
3042, 2968, 2920, 1646, 1634, 1616, 1592, 1492, 1358 cm-1; HRMS m/z 511.1798 [M-H]+ 
(calcd. for C31H28N2O3Cl 511.1788). 
 
6-(5-(4-Bromophenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-2,2,8,8-tetramethyl-2,8-
dihydropyrano[2,3-f]chromen-5-ol (5c) yellow solid; Yield 79%; mp 176-177 oC; IR υmax 
3041, 2963, 2916, 1633, 1616, 1592, 1488, 1357 cm-1; HRMS m/z 555.1287 [M-H]+ (calcd. 
for C31H28N2O3Br 555.1283). 
 
6-(5-(2-Fluorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-2,2,8,8-tetramethyl-2,8-
dihydropyrano[2,3-f]chromen-5-ol (5d) brown solid; Yield 70%; mp 119-120 oC; 19F NMR 
(376 MHz, CDCl3) δ -119.08; IR υmax 3057, 2978, 2929, 1644, 1631, 1614, 1590, 1500, 1486, 
1366 cm-1; HRMS m/z 495.2098 [M-H]+ (calcd. for C31H28N2O3F 495.2084). 
 
6-(5-(3-Fluorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-2,2,8,8-tetramethyl-2,8-
dihydropyrano[2,3-f]chromen-5-ol (5e) brown solid; Yield 66%; mp 166-167 oC; 19F NMR 
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(376 MHz, CDCl3) δ -111.78; IR υmax 2974, 2924, 1641, 1610, 1588, 1499, 1363 cm
-1; 
HRMS m/z 495.2092 [M-H]+ (calcd. for C31H28N2O3F 495.2084) 
 
6-(5-(4-Fluorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-2,2,8,8-tetramethyl-2,8-
dihydropyrano[2,3-f]chromen-5-ol (5f) brown solid; Yield 60%; mp 110 - 111 o C; 19F NMR 
(376 MHz, CDCl3) δ -111.78; IR υmax 3041, 2975, 2923, 1633, 1593, 1497, 1358 cm
-1; 
HRMS m/z 495.2092 [M-H]+ (calcd. for C31H28N2O3F 495.2084). 
 
6-(5-(2,4-Difluorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-2,2,8,8-tetramethyl-2,8-
dihydropyrano[2,3-f]chromen-5-ol (5g) yellow solid; Yield 70%; mp 171-172 oC; 19F NMR 
(376 MHz, CDCl3) δ -110.95 (d, J = 6.77 Hz), -115.02 (d, J = 7.14 Hz); IR υmax 3057, 2973, 




dihydropyrano[2,3-f]chromen-5-ol (5h) brown solid; Yield 85%; mp 138-139 oC; 19F NMR 
(376 MHz, CDCl3) δ -136.75 (d, J = 21.4 Hz), -139.12 (d, J = 21.4 Hz); IR υmax 3055, 2968, 




2,8-dihydropyrano[2,3-f]chromen-5-ol (5i) yellow solid; Yield 80%; mp 130-131 oC; 19F 
NMR (376 MHz, CDCl3) δ -59.01;  IR υmax 2974, 2926, 2854, 1643, 1629, 1589, 1499, 1363, 





2,8-dihydropyrano[2,3-f]chromen-5-ol (5j) yellow solid; Yield 88%; mp 62-63 oC; 19F NMR 
(376 MHz, CDCl3) δ -62.58; IR υmax 2975, 2928, 1641, 1593, 1499, 1325 cm
-1; HRMS m/z 
545.2064 [M-H]+ (calcd. for C32H28N2O3F3 545.2052). 
 
2,2,8,8-Tetramethyl-6-(1-phenyl-5-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-pyrazol-3-yl)-
2,8-dihydropyrano[2,3-f]chromen-5-ol (5k) yellow solid; Yield 71%; mp 168-169 oC; 19F 
NMR (376 MHz, CDCl3) δ -62.51; IR υmax 2975, 2928, 1645, 1631, 1591, 1499, 1360, 1323 




In vitro antioxidant studies 
All synthesized compounds were screened for their antioxidant properties using the DPPH 
radical scavenging and the H2O2 scavenging assay.  These assays were chosen since they 
were "in house" assays that provide a good indication of antioxidant activity. 
DPPH radical scavenging activity 
Free radical scavenging activity was determined by using the 2,2'-diphenyl-1-picrylhydrazyl 
(DPPH) method described by Burits and Bucar [32].  The synthesized compounds were 
dissolved in methanol and made to various concentrations of which 1 mL was added to 4 mL 
of a 0.004% solution of DPPH made up in methanol.  After a 30 min incubation period at 
room temperature, the absorbance was read against a methanol blank at 517 nm.  The 
percentage scavenging activity of free radicals by DPPH was calculated by using the 
following equation: 
% scavenging activity = [(A control – A sample) / A blank] x 100. 
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Where A control is the absorbance of the control reaction (containing all reagents except the 
test compound), and A sample is the absorbance of the test compound. 
H2O2 scavenging activity 
The H2O2 scavenging activity of pyrazolines was determined according to the method of 
Ruch et al. [33].  A solution of H2O2 (40 mM) was prepared in phosphate buffer (pH 7.4).  
Different concentrations of compounds made up in 3.4 mL phosphate buffer were added to 
the H2O2 solution (0.6 mL).  The absorbance value of the reaction mixture was recorded at 
230 nm.  The % scavenging activity was calculated as follows: 
% scavenging activity = [(A control – A sample) / A blank] x 100,  
Where "A control" is the absorbance of the control reaction (containing all reagents except 
the test compound), and "A sample" is the absorbance of the test compound. 
 
Antimicrobial assay 
Antifungal/antibacterial agents: All the synthesized compounds were dissolved in DMSO 
and diluted accordingly before being assayed.  Amphotericin-B and neomycin were 
purchased from Sigma Aldrich and used as reference drugs for antifungal and antibacterial 
assays respectively.  The final concentration of the test compounds ranged from 0.0012 to 
200 µg/mL.  Amphotericin-B ranged from 0.0015 to 100 µg/mL and neomycin from 0.0076 
to 500 µg/mL.  All drug dilutions were carried out in 96-well flat bottom microtitre plates.  
The final concentration of DMSO in each well was 2 nM or 0.001%. 
 
Antifungal susceptibility test:  Evaluation of the susceptibility of Candida albicans and 
non-Candida albicans species to the synthesized compounds were performed using the broth 
microdilution method according to M27-A2 for yeast guidelines.  Yeast strains were grown 
aerobically overnight at 35 °C on Sabouraud dextrose agar plates.  Yeasts were harvested and 
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suspended in 1% sterile saline solution and the turbidity of the supernatants measured 
spectrophotometrically at 625 nm with an absorbance of 0.08 - 0.1 equivalents to a 0.5 
McFarland standard following the NCCLS M27-A2 guidelines.  The working suspension was 
diluted 1:20 in a mixture containing RPMI 1640 medium and 0.165 M 
morpholinepropanesulfonic acid buffered to pH 7.0.  The working suspension was further 
diluted with the medium (1:50) to obtain the final test inoculums (1-5x103 CFU mL).  The 
microtitre plates were allowed to thaw and equilibrate to room temperature under aseptic 
conditions and different concentrations of test compounds were added to each well.  Aliquots 
of working inoculum suspensions were dispensed into each well and the plates incubated in 
an aerobic environment at 35 °C for 24 h.  After incubation, 20 µL of 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt (MTS, Promega 
Corporation, Madison, USA) was added directly to each well, incubated at 37 ºC for 4 h and 
the absorbance recorded at 490 nm on a 96-well plate reader (Biotek, Powerwave XS2).  All 
analyses were performed in triplicate and data are reported as the mean ± standard error of 
the mean of ≤ 5.  
 
Antibacterial susceptibility test 
Bacterial susceptibility test was carried out using the broth microdilution method.  Cultures 
were incubated overnight for 16 - 18 h at 37 ºC and adjusted to a turbidity equivalent to that 
of a 0.5 McFarland standard.  The inoculum was adjusted to 0.08 - 0.1 to yield a stock 
suspension of 0.4-5x108 CFU/mL, which was diluted one hundred fold to obtain a working 
suspension of 106 CFU/mL at 625 nm.  Microtitre plates were placed in a laminar flow unit to 
equilibrate to room temperature under aseptic conditions.  Aliquots of 100 µL of bacterial 
inoculate were added to the microtiter plates containing different concentrations of test 
compounds.  Plates were incubated aerobically for 16 - 18 h at 37 °C.  Following incubation, 
40 µL of freshly prepared iodonitrotetrazolium chloride (INT) (2-(4-iodophenyl)-3-(4-
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nitrophenyl)-5-phenyl-2H tetrazolium chloride) solution (200 µg mL-1) was added to each 
well and the plate further incubated for 45 minutes at 37 ºC in the dark.  If the colorless INT 
is reduced to red after incubation, persistent growth of bacteria is indicated.  No color change 
denotes the lack of bacterial growth.  Neomycin was used as a control drug in this study.  All 
analyses were performed in triplicate and data are reported as the mean ± standard error of 
the mean of ≤ 5. 
 
Results and discussion 
Chemistry 
The synthesis of the pyrazolines was a three step reaction starting with the prenylation of 
2',4',6'-trihydroxyacetophenone using β-methyl crotonaldehyde.  This formed two dimethyl 
pyran rings at the 2- and 4- positions resulting in the prenylated acetophenone intermediate 2, 
which was condensed with various benzaldehydes by a Claisen-Schmidt condensation to 
form the chalcones (3a-k) at room temperature under basic conditions with potassium 
hydroxide and ethanol.  The chalcones were then converted to the pyrazolines with either 
hydrazine or phenylhydrazine to produce the corresponding pyrazoline analogues as racemic 
mixtures (4a-k and 5a-k, respectively) as illustrated in Scheme 6-1.  This reaction probably 
takes places through in situ formation of an appropriate β unsaturated hydrazone intermediate 
which immediately cyclizes to form pyrazolines.  The series of pyranochromene pyrazolines 
synthesized contained a single fluorine atom or trifluoromethyl group at the ortho, meta and 
para positions of the phenyl ring as well fluorine at the 2',4'- and 3',4'- positions on the 
phenyl ring.  These substitution patterns were chosen to observe the effect of fluorine on 
biological activity as well as to determine the best position for these groups.  For comparison, 




Scheme 6-1  General synthesis of chalcones and pyrazoline compounds.  Reagents and 
conditions: (i) 3-methy 2-butenal, pyridine, 110 °C reflux, 48 hrs; (ii) substituted 
benzaldehyde, KOH, EtOH/H2O, 5 – 16 hrs; (iii) NH2NH2, EtOH, 70 °C, 2 - 4 hrs; (iv) 
PhNHNH2, EtOH, 70 °C, 2 - 4 hrs. 
 
Structural elucidation 
The structures of the pyrazoline derivatives were established on the basis of IR and NMR 
spectroscopy (1H, 13C and 2D).  The full characterization (1H and 13C NMR assignments) of 
the pyranochromene pyrazolines 4a-k and 5a-k are presented in Table 6-1 -Table 6-4 
respectively.  The spectra of these compounds were well resolved and with the aid of HSQC, 
HMBC, COSY and NOESY data as well as multiplicity patterns, unambiguous chemical shift 
assignments were made. 
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For the pyranochromene pyrazoline, typical 1H resonances can be observed for the pyran 
rings and the pyrazoline moiety.  Taking the 3-fluoro derivative (4e) as an example (Figure 
6-1), the presence of the pyrazoline ring was indicated by the typical ABX system of H-4a (δ 
3.30, J = 17.6, 8.9 Hz), H-4b (δ 3.80, J = 17.6, 10.5 Hz) and H-3, which appeared as a triplet 
due to second order coupling at δ 4.76 (J = 9.7 Hz).  Coupling between H-3, H-4a and H-4b 
was clearly seen in the COSY spectrum.  C-3 showed HMBC correlations to H-13 (δ 7.10, d, 
J = 9.8 Hz) and H-17 (δ 7.15, d, J = 7.7 Hz), allowing these two aromatic protons to be 
distinguished from H-15 at δ 7.00 (td, J = 8.3, 2.0 Hz) and H-16 at δ 7.32 (dd, J = 13.8, 7.8 
Hz), which in turn could be distinguished by their coupling constants.  HMBC correlations 
between H-4a and H-4b with C-12 and C-5 at δ 145.5 (d, J = 6.6 Hz) and δ 154.4 allowed 
these two carbon resonances to be assigned. 
The olefinic protons on the pyran rings appeared as two pairs of doublets with J = 10.0 Hz at 
δ 6.71 (H-18) and δ 5.47 (H-19) and δ 6.61 (H-23) and δ 5.40 (H-24), each pair being 
coupled in the COSY spectrum.  HMBC correlations between these olefinic protons and the 
carbon resonances overlapping with the solvent peak at δ 77.3 allowed C-20 and C-25 to be 
assigned to this resonance.  The methyl groups, H-21/H-22 at δ 1.43 and 1.42, and H-26/H-27 
at δ 1.41 and 1.37 were assigned based on HMBC correlations with C-19 and C-24 
respectively.  The NH proton of the pyrazoline unit and the hydroxyl proton on the phenyl 
ring A appeared as two broad singlets at δ 5.73 and δ 12.36 respectively.     
 
The carbon resonance of C-8 (δ 103.2) and C-10 (δ 102.8) were assigned due to HMBC 
correlations with H-19 and H-24 respectively and C-6, the other non-oxygenated aromatic 
proton at δ 100.0 was then assigned to C-6.  The C-9 and C-11 oxygenated carbon resonances 
on the A ring at δ 150.8 and δ 152.7 could be assigned since C-9 showed HMBC correlations 
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to both H-18 and H-23 while C-11 showed HMBC correlations to H-23 only.  The C-7 
oxygenated carbon resonance at δ 155.5 was assigned as such, since it showed HMBC 
correlations to H-18.  The six carbon resonances on the fluorinated B ring each appeared as 
doublets with C-14, directly bonded to fluorine having the largest J value of 244.9 Hz, 
followed by the two carbon resonances ortho to the fluorine (C-13 at δ 113.7, J = 21.7 Hz 
and C-15 at δ 114.9,  J = 21.0 Hz), the two meta carbon resonances (C-12 at δ 145.5, J = 6.6 
Hz; C-16 at δ 130.6, J = 8.2 Hz) and the para carbon resonance at δ 122.3 (d, J = 2.8 Hz). 
The pyrazolines 5a-k had similar NMR resonances, with the exception of extra aromatic 
proton resonances between δ 6.81 to 7.23, for example H-19/23 occurring as a doublet at δ 
6.86 (J = 8.1 Hz), H-20/22 occuring as a multiplet at δ 7.16-7.23 and H-21 occurring as a 
triplet at δ 6.81 (J = 7.6 Hz). 
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Table 6-1  1H NMR data of pyranochromene pyrazolines 4a – 4k (400 MHz, CDCl3, J in Hz) 
No. 4a 4b 4c 4d 4e 4f 4g 4h* 4i 4j 4k 
OH 12.39 (bs) 12.36 (bs) 12.35 (bs) 12.39 (bs) 12.36 (bs) 12.39 (bs) 12.39 (bs) 12.30 (bs) 12.35 (bs) 12.38 (bs) - 
NH 5.72-5.80 
(bs) 
5.70 (bs) 5.71 (bs) - 5.73 (bs) 5.70 (bs) - 5.72 (bs) 5.76 (bs) - - 
3 5.18 (t, 9.8) 4.74 (t, 9.7) 4.73 (t, 9.7) 5.05 (t, 9.7) 4.76 (t, 9.7) 4.75 (t, 9.7) 5.03 (t, 9.8) 4.73 (t, 9.9) 5.19 (t, 9.9) 4.83 (t, 
10.2) 
4.85 (t, 9.7) 












































13 - 7.32 (bs) 7.26 (d, 
8.3) 






- 7.66 (s) 7.51 (d, 
8.0) 
14 7.39 (dd, 
7.6, 1.1) 




- 7.03 (t, 8.5) 6.89 - 6.80 
(m) 
- 7.66 (d, 
7.9) 



















7.03 (t, 8.5) 6.89 - 6.80 
(m) 
7.11 - 7.16 
(m) 
7.56 (t, 7.6) 7.48 (t, 7.7) 7.62 (d, 
8.0) 
17 7.59 (dd, 
7.6, 1.5) 































































21 1.43 (s) 1.43 (s) 1.43 (s) 1.42 (s) 1.43 (s) 1.43 (s) 1.43 (s) 1.43 (s) 1.43 (s) 1.44 (s) 1.43 (s) 
22 1.42 (s) 1.42 (s) 1.42 (s) 1.40 (s) 1.42 (s) 1.42 (s) 1.43 (s) 1.42 (s) 1.42 (s) 1.43 (s) 1.42 (s) 












































26 1.42 (s) 1.40 (s) 1.40 (s) 1.39 (s) 1.40 (s) 1.40 (s) 1.42 (s) 1.41 (s) 1.39 (s) 1.41 (s) 1.40 (s) 





Table 6-2  13C NMR data of pyranochromene pyrazolines 4a – 4k (100 MHz, CDCl3, J in Hz) 
No. 4a 4b 4c 4d† 4e 4f 4g* 4h* 4i 4j 4k 
3 59.2 62.1 62.1  62.2 (d, 1.4) 62.0 55.3 61.9 57.8 62.4 62.3 
4 44.0 45.9 45.9  45.8 45.9 44.3 46.0 46.4 46.0 46.0 
5 154.5 154.4 154.4  154.4 154.4 154.7 154.3 154.0 154.4 154.4 
6 100.1 100.0 100.0  100.0 100.0 100.0 99.9 99.9 99.9 99.9 
7 155.5 155.5 155.5  155.5 155.5 155.5 155.5 155.5 155.5 155.5 
8 103.2 103.2 103.2  103.2 103.2 103.2 103.2 103.2 103.2 103.2 
9 150.7 150.8 150.8  150.8 150.7 150.8 150.9 150.8 150.8 150.9 
10 102.8 102.8 102.8  102.8 102.8 102.8 102.8 102.8 102.8 102.8 
11 152.7 152.6 152.6  152.7 152.6 152.7 152.7 152.7 152.7 152.7 




- 139.8 (t, 
2.92) 
141.8 143.8 146.8 








123.2# 123.8 (q, 
3.8) 
127.2 






















127.7 124.8 (q, 
3.8) 
## 








132.9 129.6 126.0 (q, 
3.8) 








127.8 130.2 127.2 
18 127.5 117.2 117.2  117.2 117.2 117.2 117.2 117.2 117.2 117.2 
19 129.9 125.9 125.9  125.9 125.9 125.9 125.9 125.9 125.9 126.0 
20 77.3 77.3 77.3  77.3 77.3 77.4 77.4 77.3 77.4 77.4 
21 28.3 28.3 28.3  28.3 28.3 28.30 28.29 28.3 28.3 28.3 
22 28.2 28.2 28.2  28.2 28.2 28.26 28.26 28.2 28.2 28.2 
23 127.4 117.0 117.0  117.1 117.1 117.1 117.1 117.0 117.0 117.0 
24 128.9 125.2 125.2  125.2 125.2 125.2 125.2 125.3 125.2 125.2 
25 77.2 77.3 77.3  77.3 77.3 77.4 77.3 77.3 77.4 77.4 
26 28.0 28.0 28.0  28.0 28.0 28.02 28.02 28.0 28.01 28.0 
27 27.9 27.8 28.0  28.0 28.0 27.98 28.00 27.8 27.97 27.9 




Table 6-3  1H NMR data of pyranochromene N-pyrazolines 5a – 5k (400 MHz, CDCl3, J in Hz) 
No. 5a 5b 5c 5d 5e 5f 5g 5h 5i 5j 5k 


















5.60 - 5.50 
(m) 



























































 7.23 - 7.21 
( m) -





















7.23 – 7.16 
(m) 
- - 




- - - 
7.47 – 7.44 
(m) 
7.47 – 7.44 
(m) 
- 

































7.28 – 7.22 
(m) 
7.21 (t, 7.8) 
7.14 - 7.07 
(m) 
7.47 - 7.44 
(m) 






































7.21 (t, 7.8) 
































































5.60 – 5.50 
(m) 




27 1.45 (s) 1.44 (s) 1.48 (s) 1.45 (s) 1.45 (s) 1.38 (s) 1.45 (s) 
1.37 – 1.36 
(m) 1.45 (s)
 1.45 (s) 1.45 (s) 
28 1.45 (s) 1.43 (s) 1.48 (s) 1.43 (s) 1.44 (s) 1.36 (s) 1.43 (s) 1.35 (s) 1.43 (s) 1.43 (s) 1.44 (s) 










































32 1.43 (s) 1.40 (s) 1.44 (s) 1.42 (s) 1.41 (s) 1.33 (s) 1.42 (s) 1.33 (s) 1.39 (s) 1.39 (s) 1.41 (s) 




Table 6-4  13C NMR shifts of pyranochromene N-pyrazolines 5a – 5k (100 MHz, CDCl3, J in Hz) 
No. 5a 5b 5c 5d 5e 5f 5g 5h 5i 5j 5k 
3 60.2 63.0 63.0 56.5 (d, 
2.7) 
63.1 62.8 56.2 (d, 
2.0) 
62.6 59.1 63.3 63.1 
4 46.6 48.2 48.1 46.8 48.1 48.3 46.8 48.1 48.3 48.2 48.1 
5 150.6 150.1 150.1 150.6 150.2 150.1 150.6 150.1 150.0 150.2 150.2 
6 100.0 99.9 99.9 100.0 99.9 99.9 99.9 99.8 99.9 99.8 99.8 
7 154.8 154.8 154.8 154.8 154.9 154.8 154.6 154.8 154.8 154.9 154.8 
8 103.2 103.3 103.1 103.2 103.3 103.3 103.3 103.3 103.2 103.3 103.3 
9 150.8 150.9 151.0 150.9 150.9 150.8 150.9 151.0 150.9 151.0 151.0 
10 103.1 103.1 103.0 103.1 103.1 103.0 103.1 103.1 103.1 103.1 103.1 
11 152.8 152.8 152.8 152.8 152.8 152.7 152.6 152.7 152.8 152.8 152.8 




# 139.8 (t, 
3.9) 
141.1 144.0 146.9 











































133.3 124.8 (q, 
3.8) 
- 










127.8 130.0 126.5 (d, 
3.8) 








122.2  (dd, 
5.9, 3.6) 
127.4 129.7 126.7 
18 144.4 144.6 144.6 144.5 144.7 144.7 144.4 144.5 144.0 144.7 144.6 
19/23 113.1 113.3 113.4 113.1 113.4 113.4 113.2 113.4 113.0 113.5 113.4 
20/22 129.4 129.3 129.3 129.3 129.3 129.3 129.4 129.4 129.4 129.4 129.4 
21 119.7 119.9 119.9 119.7 119.9 119.8 119.9 120.1 119.6 120.1 120.0 
24 117.1 117.1 117.1 117.1 117.1 117.1 117.0 117.03 117.0 117.04 117.04 
25 126.2 126.2 126.2 126.2 126.2 126.2 126.2 126.3 126.2 126.2 126.3 
26 77.5 77.5 77.5 77.5 77.4 77.4 77.4 77.4 77.5 77.4 77.4 
27 28.3 28.3 28.3 28.3 28.3 28.3 28.3 28.3 28.3 28.3 28.3 
28 28.2 28.2 28.2 28.2 28.2 28.2 28.2 28.2 28.2 28.2 28.2 
29 116.9 117.0 117.0 116.9 117.0 117.0 116.9 116.98 116.9 116.96 116.98 
30 125.3 125.3 125.3 125.3 125.3 125.3 125.4 125.3 125.4 125.3 125.3 
31 77.3 77.3 77.3 77.3 77.3 77.3 77.4 77.4 77.3 77.3 77.4 
32 28.1 28.0 28.0 28.1 28.1 28.1 28.1 28.1 28.0 28.0 28.08 
33 28.0 28.0 28.0 28.0 28.0 28.0 28.0 28.0 27.8 28.0 28.04 










All of the synthesized pyrazoline analogues were screened for their in vitro anti-bacterial 
activity against Gram +ve (Staphylococcus aureus (43300) and Enterococcus faecalis (5129)) 
and Gram -ve (Escherichia coli (35218), Klebsiella pneumoniae (700603) and Pseudomonas 
aeruginosa (27853)) strains of bacteria.  The observed anti-bacterial activities are shown in 
(Table 6-5).  Pyrazoline and N-pyrazoline analogues 4b, 5b (p-Cl) and 4e, 5e (m-F) 
displayed good activity against both Gram +ve bacteria with MIC values between 14.9 to 
57.2 µM.  Of these compounds, the best activity was shown by 4e with an MIC of 14.9 µM 
against P. aeruginosa, similar to the standard neomycin, which had an MIC of 16.3 µM 
against the same bacterial species.  Compounds 4i and 5i (o-CF3) and 4j (m-CF3) showed 
excellent activity against the Gram –ve bacterial species, with 4i having similar activity (MIC 
of 13.3 µM) to neomycin (16.3 µM) against P. aeruginosa.   
 
Compounds 4c and 5c (4-Br), 4f (4-F), and 4h and 5h (3,4-F) showed good activity against 
all the fungal species tested against, on average 8-10 times higher than the standard, 




Antioxidant properties of the synthesized compounds were tested by both the DPPH radical 
scavenging activity (testing the ability of the compounds to scavenge free radicals) and H2O2 
scavenging activity (testing the ability to scavenge hydroxyl radicals).  These results are 
presented in Table 6-6.  With the exception of the 3,4-difluoro (4h and 5h) and the 
trifluoromethyl compounds (4i, 5i, 4j, 5j, 4k and 5k), all other compounds showed very good 
antioxidant activity, comparable to or better than ascorbic acid, which was used as a control.  
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The pyrazolines 4c and 5c (4-Br), and the monofluorinated compounds 5d (2-F), 4e and 5e 
(3-F), and 4f and 5f (4-F) exhibited excellent antioxidant activity with IC50 values of between 
48.4-63.0 µM for the DPPH assay and 79.7-95.6 µM for the H2O2 assay.   
 
 
Table 6-5  Antimicrobial activity of the synthesized compounds 
No. Minimum inhibitory concentrations (µM) 
Antibacterial Antifungal 

















4a 57.2 57.2 - - - - - - - 
5a 48.7 97.5 - - - - - - - 
4b 28.6 57.2 57.2 57.2 57.2 228.9 228.9 228.9 457.7 
5b 24.4 48.7 48.7 48.7 48.7 97.5 97.5 97.5 121.8 
4c - - 104.1 104.1 208.2 52.0 52.0 104.1 52.0 
5c - - 89.7 89.7 89.7 44.8 44.8 - 112.1 
4d - - - - - - - - - 
5d - 402.8 - - - 201.4 201.4 402.8 201.4 
4e 29.7 29.7 29.7 14.9 29.7 - - - - 
5e 25.2 50.4 50.4 50.4 50.4 - - - - 
4f 148.6 148.6 237.8 237.8 237.8 59.5 59.5 29.7 59.5 
5f 125.9 125.9 201.4 201.4 201.4 - - - - 
4g 57.0 57.0 - - - 456.1 456.1 - 456.1 
5g 48.6 48.6 - - - 194.3 194.3 - - 
4h 228.1 456.1 - - - 57.0 57.0 28.5 57.0 
5h 194.3 388.7 - - - 48.6 48.6 48.6 48.6 
4i 212.6 53.1 26.6 13.3 26.6 - - - - 
5i 183.0 45.7 22.9 22.9 22.9 - - - - 
4j 106.3 106.3 26.6 26.6 26.6 132.8 212.6 425.1 425.1 
5j 91.5 91.5 45.7 91.5 91.5 114.4 183.0 365.9 365.9 
4k 106.3 212.6 53.1 53.1 53.1 - - - - 
5k 183.0 183.0 91.5 114.4 91.5 - - - - 
C1* 16.3 32.5 16.3 16.3 16.3 - - - - 
C2** - - - - - 6.8 6.8 3.4 3.4 
 


















4a 126.2 103.4 4g 131.25 126.35 
5a 117.3 84.5 5g 89.40 85.35 
4b 145.1 115.0 4h 175.45 167.63 
5b 103.4 95.3 5h >388.7 184.58 
4c 55.2 89.24 4i >365.9 >183.0 
5c 48.4 95.57 5i >425.1 >212.6 
4d 114.3 134.96 4j - >457.4 
5d 59.9 85.14 5j - >531.4 
4e 57.98 90.80 4k >183.0 128.1 
5e 50.99 79.69 5k >212.6 127.9 
4f 62.95 90.90 Ascorbic  
acid 
220.02 187.71 




A series of novel halogen substituted pyranopyrazolines and N-pyrazoline analogues (4a - 4k 
and 5a – 5k) were easily synthesized and evaluated for their antimicrobial and antioxidant 
activities.  Amongst the synthesized compounds, 4e (3-F) and 4i (2-CF3) were found to have 
excellent activity against the Gram -ve P. aeruginosa (MICs of 14.9 and 13.3 µM, 
respectively).  Compound 4e showed the best broad spectrum activity with MICs of 29.7 µM 
for all the other bacterial strains tested against.  Compounds 4i, 5i (2-CF3) and 4j (3-CF3) 
showed excellent activity against the Gram –ve strains only, with MICs between 13.3 and 
26.6 µM.  The best antifungal activity was shown by 4f (29.7 µM) and 4h (28.5 µM) against 
C. krusei.  The monofluorinated compounds 5d, 4e, 5e, 4f and 5f and the bromo compounds 
4c and 5c showed excellent antioxidant activity, much better than that of ascorbic acid with 
IC50 values of between 48.4-63.0 µM for the DPPH assay and 79.7-95.6 µM for the H2O2 
assay.  The compounds synthesized here could be lead compounds for antibacterial activity 
and possible antioxidant supplements.   The data indicate that the both the F and CF3 groups 
result in good activity of the pyranopyrazolines with the ortho and meta positions on the 
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phenyl ring showing better activity than the para position. 
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Chapter 7. Conclusion 
The aim of the study was to synthesise novel pyranochromene chalcones, which were to be 
tested for their antimicrobial and antioxidant activity as it was hypothesized that the 
chromene moiety would make a difference to the bioactivity of the molecules.  The chromene 
moiety was chosen to be studied since molecules isolated or synthesized previously 
containing a chromene moiety had shown good bioactivity [1, 2].  
 
In total, 20 pyranochromene chalcones were synthesized, of which 18 were novel.  These 
pyranochromene chalcones were synthesized by adding the pyran moiety onto 2,4,6-
trihydroxyacetophone using 3-methyl-2-butenal in the presence of pyridine forming the 
dipyrano acetophenone, before condensing it with various substituted benzaldehydes as well 
as naphthalene-2-carbaldehyde, furan-2-carbaldehyde and pyridine-2-carbaldehylde 
(picolinaldehyde).  The varying substituents on benzaldehyde included halogens, methoxy, 
trifluoromethyl and nitro groups.   
 
Two series of pyranochromene chalcones (those with halogens, methoxy and nitro phenyl 
moieties and the naphthyl moiety) were cyclized with NaOAc to the flavanones.  A total of 
13 flavanones were synthesized, of which 12 were novel.  In addition, a flavone was also 
synthesized.  The halogenated and trifluoromethylated chalcones were also converted to 
pyrazolines using either hydrazine or phenylhydrazine to prepare pyrazoline derivatives of 
the pyranochalcones.  A total of 22 pyrazoline derivatives were synthesized, of which all 
were novel. 
 
In general, the syntheses were fairly easy and the compounds were prepared in good yields.  
The α,β-unsaturated ketone moiety of the chalcones were reactive and this reactivity was 
123 
 
taken advantage of to make two other series of molecules, the flavanones and the pyrazolines, 
which could also be tested for bioactivity. 
 
A full structural elucidation of each set of compounds was carried out using 2D NMR and X-
ray crystallography.  Unequivocal NMR assignments for each set of compounds were carried 
out and will provide a nice basis for identification and assignment of resonances for 
compounds with similar structures.  In addition, the crystal structures for several compounds 
were obtained, which established the trans configuration of the double bond and the planarity 
of the synthesized chalcones.  In addition, X-Ray crystallography was also used to determine 
the absolute configuration at C-2 of the flavanones as S. 
 
The synthesized compounds were tested for their antibacterial, antifungal and antioxidant 
activity.  The unsubstituted flavanone A-4a (MIC between 18.7-64.4 µM) showed the best 
antibacterial activity, followed by the 2-chloroflavanone A-4i (MICs between 29.6-118.2 
µM), the unsubstituted chalcone A-3a (MICs between 32.2-128.7 µM), and lastly the 4-
methoxychalcone A-3g (MICs between 119.5-239.0 µM).  In some cases, the synthesized 
compounds had similar activity to the standard, neomycin (8.1-32.5 µM).  The para NO2 
flavone A-5 showed excellent activity against S. aureus at 2.3 µM, far better than neomycin 
at 16.3 µM.  This flavone could be an excellent lead for an anti-Staphylococcal antibiotic.  
The 2-trifluoromethyl pyranochromene chalcone B-6 showed excellent antibacterial activity 
against all Gram negative strains (13.7-27.5 µM), comparable to the control neomycin (16.3 
µM). 
 
The chalcones A-3a (unsubstituted), A-3d (4-fluoro) and A-3m (naphthyl) and the flavanones 
A-4a (unsubstituted), A-4d (4-fluoro), A-4f (3-methoxy) and A-4l (3-nitro) all showed good 
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activity against all four strains of fungi having MIC values of 28.5 to 64.4 µM.  The standard 
amphotericin B used for comparison showed lower activity with MIC values of between 1.3-
5.4 µM.  However, the activity of the chalcones and flavanones is still good and these 
compounds may have fewer side effects than drugs currently on the market.     
 
With the exception of a few compounds, the antioxidant activity of most chalcones was 
comparable to that of the control, ascorbic acid (IC50 of 220.0 µM).  The chalcones that 
showed the best activity were A-3e (2,4-difluoro) (IC50 of 230.4 µM), A-3h (2-fluoro-3-
methoxy) (IC50 of 233.2 µM), A-3i (2-chloro) (IC50 of 228.7 µM) and A-3l (3-nitro) (IC50 of 
220.3 µM).  The flavanones A-4i (2-chloro) (IC50 of 225.8 µM) and A-4l (3-nitro) (IC50 of 
234.7 µM) also showed good antioxidant activity.  These results indicated that halogenation 
at C-2 of the phenyl ring or nitration or methoxylation at C-3 results in good antioxidant 
activity of the prenylated chalcones and flavanones. 
 
The pyrazoline C-4e (3-fluoro derivative) showed good antibacterial activity against both 
Gram positive and Gram negative strains with IC50 values of between 14.9-29.7 µM.  The 2-
trifluoromethyl derivative C-4i showed good antibacterial activity against the Gram negative 
strains only with IC50 values of between 13.3-26.6 µM in comparison to neomycin, which 
showed activity in the same assay at 16.3-32.5 µM for the Gram positive strains and 16.3 µM 
for the Gram negative strains.  Several pyrazolines showed better antioxidant activity than the 
standard ascorbic acid, with IC50 values up to four times lower in both the DPPH and the 
H2O2 assay. 
 
With regard to structure activity relationship, these results indicate that pyran groups on the 
chalcone or flavanone skeleton is a good scaffold for antifungal activity and that this activity 
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can be increased by fluoro, methoxy and nitro groups being substituted on the phenyl ring or 
by substituting the phenyl ring with a naphthalene group.  It was further found that the CF3 
moiety is a good substituent for antimicrobial activity, better than other heterocyclic rings and 
the fluoro substituent.  The best position for this group with regard to antibacterial activity is 
C-2 on the B ring of the chalcone and C-4 on the same ring with regard to antifungal activity.  
For the pyranopyrazolines, the F and CF3 groups result in good activity with the ortho and 
meta positions on the phenyl ring showing better activity than the para position. 
 
In conclusion, several of the synthesized compounds can be considered leads in finding drugs 
with antibacterial, antifungal and antioxidant activities.  The most promising leads for broad 
spectrum antibiotics are the unsubstituted pyranochromene flavanone (A-4a) and the 3-fluoro 
pyrazoline derivative (C-4e), whilst the 2-trifluoromethyl pyranochromene chalcone (B-6) 
and its pyrazoline derivative (C-4i) are good leads for Gram negative antibiotics and the p-
nitropyranochromene flavone derivative, an excellent lead for a S. aureus strain specific 
antibiotic.  Several of the pyranochromene chalcones mentioned above could be good 
antifungal and antioxidant leads, whilst several pyrazolines can also be considered good leads 
for antioxidant activity.  The mechanism of action of their antimicrobial and antioxidant 
activity could be due to their ability to complex with metals [3] or their ability to interact with 
cell membranes [4]. 
 
Future work can be carried out on these lead molecules to see if they can be developed 
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